A	O
transcriptional	O
block	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
at	O
the	O
-150	B-DNA
AP-1	I-DNA
site	I-DNA
in	O
effector	B-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Both	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
produce	O
IL-2	B-protein
in	O
response	O
to	O
Ag	O
recognition	O
have	O
been	O
isolated	O
.	O

However	O
,	O
most	O
effector	B-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
recovered	O
after	O
exposure	O
to	O
Ag	B-protein
do	O
not	O
produce	O
sufficient	O
IL-2	B-protein
to	O
sustain	O
growth	O
,	O
and	O
depend	O
on	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
cells	I-cell_type
for	O
this	O
obligate	O
growth	O
factor	O
.	O

IL-2	O
expression	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
primarily	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
,	O
but	O
mechanisms	O
restricting	O
IL-2	O
production	O
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O

To	O
evaluate	O
transcriptional	O
regulation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
stably	O
transfected	O
reporter	B-DNA
genes	I-DNA
into	O
Ag	B-protein
-specific	O
CD8+	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

CD28+	B-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
unable	O
to	O
transcribe	O
the	O
IL-2	B-DNA
gene	I-DNA
in	O
response	O
to	O
antigenic	O
stimulation	O
had	O
a	O
block	O
in	O
transactivation	O
of	O
the	O
-150	B-DNA
CD28	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CD28RE	I-DNA
)	I-DNA
/AP-1	I-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
but	O
did	O
transactivate	O
the	O
composite	O
NFAT/AP-1	B-DNA
and	I-DNA
OCT/AP-1	I-DNA
sites	I-DNA
,	O
and	O
a	O
consensus	B-DNA
AP-1	I-DNA
motif	I-DNA
.	O

Mutation	O
of	O
the	O
nonconsensus	B-DNA
-150	I-DNA
AP-1	I-DNA
site	I-DNA
to	O
a	O
consensus	B-DNA
AP-1	I-DNA
site	I-DNA
,	O
or	O
insertion	O
of	O
a	O
CD28RE/AP-1	B-DNA
consensus	I-DNA
site	I-DNA
upstream	O
of	O
the	O
native	O
-150	B-DNA
CD28RE/AP-1	I-DNA
site	I-DNA
restored	O
transactivation	O
of	O
the	O
altered	O
promoter	B-DNA
.	O

These	O
results	O
suggest	O
that	O
the	O
defect	O
at	O
the	O
-150	B-DNA
site	I-DNA
may	O
reflect	O
the	O
absence	O
or	O
inactivity	O
of	O
a	O
required	O
factor	O
rather	O
than	O
repression	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

.	NULL

2	NULL
nozzles	NULL
per	NULL
well	NULL
enable	NULL
cell	NULL
Check	NULL
out	NULL
how	NULL
Lamma_	NULL
r	NULL
Was_h	NULL
washing	NULL
by	NULL
creating	NULL
a	NULL
Infoinar	NULL
.	NULL

CURlOX	NULL
systems	NULL
replace	NULL
centrifugation	NULL
uean	NULL
completely	NULL
in	NULL
handling	NULL
cells	NULL
Accelerating	NULL
Life	NULL
Scie	NULL
See	NULL
How	NULL
It	NULL
Works	NULL
go	NULL
meJournal	NULL
if	NULL
A	NULL
Transcriptional	NULL
Block	NULL
in	NULL
the	NULL
IL-2	NULL
Promoter	NULL
111111111110	NULL
0	NULL
gy	NULL
at	NULL
the	NULL
-150	NULL
AP-1	NULL
Site	NULL
in	NULL
Effector	NULL
CD8+*	NULL
T	NULL
Cells	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
__	NULL
Rosalyode	NULL
J.	NULL
Finch	NULL
,	NULL
Patrick	NULL
E.	NULL
Fields	NULL
and	NULL
Philip	NULL
D.	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Greenberg	NULL
J	NULL
Immunol	NULL
2001	NULL
;	NULL
166:6530-6536	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.166.11.6530	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/11/6530	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
49	NULL
articles	NULL
,	NULL
29	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/11/6530.full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
A	NULL
Transcriptional	NULL
Block	NULL
in	NULL
the	NULL
IL-2	NULL
Promoter	NULL
at	NULL
the	NULL
-150	NULL
AP-1	NULL
Site	NULL
in	NULL
Effector	NULL
CD8*	NULL
T	NULL
Cells	NULL
!	NULL

Rosalynde	NULL
J.	NULL
Finch	NULL
,	NULL
*	NULL
Patrick	NULL
E.	NULL
Fields	NULL
,	NULL
``	NULL
and	NULL
Philip	NULL
D.	NULL
Greenberg****	NULL
Both	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
that	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
recognition	NULL
have	NULL
been	NULL
isolated	NULL
.	NULL

However	NULL
,	NULL
most	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
recovered	NULL
after	NULL
exposure	NULL
to	NULL
Ag	NULL
do	NULL
not	NULL
produce	NULL
sufficient	NULL
IL-2	NULL
to	NULL
sustain	NULL
growth	NULL
,	NULL
and	NULL
depend	NULL
on	NULL
CD4*	NULL
T	NULL
helper	NULL
cells	NULL
for	NULL
this	NULL
obligate	NULL
growth	NULL
factor	NULL
.	NULL

IL-2	NULL
expression	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
is	NULL
primarily	NULL
controlled	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
,	NULL
but	NULL
mechanisms	NULL
restricting	NULL
IL-2	NULL
production	NULL
in	NULL
CD8*	NULL
T	NULL
cells	NULL
have	NULL
not	NULL
been	NULL
elucidated	NULL
.	NULL

To	NULL
evaluate	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
stably	NULL
transfected	NULL
reporter	NULL
genes	NULL
into	NULL
Ag-specific	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

CD28*	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
unable	NULL
to	NULL
transcribe	NULL
the	NULL
IL-2	NULL
gene	NULL
in	NULL
response	NULL
to	NULL
antigenic	NULL
stimulation	NULL
had	NULL
a	NULL
block	NULL
in	NULL
transactivation	NULL
of	NULL
the	NULL
-150	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
/	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
but	NULL
did	NULL
transactivate	NULL
the	NULL
composite	NULL
NFAT/AP-1	NULL
and	NULL
OCT/AP-1	NULL
sites	NULL
,	NULL
and	NULL
a	NULL
consensus	NULL
AP-1	NULL
motif	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
nonconsensus	NULL
-150	NULL
AP-1	NULL
site	NULL
to	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
,	NULL
or	NULL
insertion	NULL
of	NULL
a	NULL
CD28RE/AP-1	NULL
consensus	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
native	NULL
-150	NULL
CD28RE/AP-1	NULL
site	NULL
restored	NULL
transactivation	NULL
of	NULL
the	NULL
altered	NULL
promoter	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
defect	NULL
at	NULL
the	NULL
-150	NULL
site	NULL
may	NULL
reflect	NULL
the	NULL
absence	NULL
or	NULL
inactivity	NULL
of	NULL
a	NULL
required	NULL
factor	NULL
rather	NULL
than	NULL
repression	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2001	NULL
,	NULL
166	NULL
:	NULL
6530-6536.	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
more	NULL
recent	NULL
experi-	NULL
ments	NULL
have	NULL
shown	NULL
that	NULL
activated	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
can	NULL
also	NULL
produce	NULL
IL-2	NULL
,	NULL
CD4	NULL
*	NULL
T	NULL
helper	NULL
cells	NULL
represent	NULL
the	NULL
dominant	NULL
IL-2-pro-ducing	NULL
population	NULL
.	NULL

CD8*	NULL
T	NULL
cells	NULL
mediating	NULL
long	NULL
term	NULL
in	NULL
vivo	NULL
effector	NULL
responses	NULL
depend	NULL
on	NULL
IL-2	NULL
produced	NULL
by	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
sustain	NULL
proliferation	NULL
and	NULL
promote	NULL
survival	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

Although	NULL
CD8	NULL
*	NULL
responses	NULL
to	NULL
viruses	NULL
can	NULL
be	NULL
elicited	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
establishment	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
memory	NULL
is	NULL
severely	NULL
compromised	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
a	NULL
dominant	NULL
pathway	NULL
for	NULL
CD4	NULL
T	NULL
cell	NULL
help	NULL
is	NULL
via	NULL
CD40	NULL
ligand-mediated	NULL
activation	NULL
of	NULL
APC	NULL
(	NULL
7-9	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
recent	NULL
report	NULL
has	NULL
reaffirmed	NULL
the	NULL
importance	NULL
of	NULL
direct	NULL
CD4	NULL
*-to-CD8*	NULL
T	NULL
cell	NULL
communication	NULL
by	NULL
way	NULL
of	NULL
lym-phokines	NULL
(	NULL
10	NULL
)	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
cells	NULL
capable	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
have	NULL
been	NULL
isolated	NULL
in	NULL
selected	NULL
settings	NULL
,	NULL
and	NULL
maintenance	NULL
of	NULL
the	NULL
ability	NULL
to	NULL
express	NULL
IL-2	NULL
appears	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
concurrent	NULL
costimulation	NULL
with	NULL
each	NULL
activation	NULL
cycle	NULL
.	NULL

However	NULL
,	NULL
costimulation	NULL
is	NULL
not	NULL
required	NULL
for	NULL
the	NULL
retention	NULL
of	NULL
cytolytic	NULL
function	NULL
,	NULL
a	NULL
phenomenon	NULL
termed	NULL
``	NULL
split	NULL
anergy	NULL
``	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
potential	NULL
for	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
sufficient	NULL
costimulatory	NULL
activity	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
generation	NULL
of	NULL
potent	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
tumors	NULL
independent	NULL
of	NULL
CD4	NULL
responses	NULL
following	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
B7-transfected	NULL
tumor	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
cells	NULL
appear	NULL
to	NULL
I	NULL
nterleukin-2	NULL
was	NULL
first	NULL
described	NULL
as	NULL
a	NULL
lymphokine	NULL
produced	NULL
by	NULL
Department	NULL
of	NULL
*Immunology	NULL
and	NULL
*Medicine	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98195	NULL
;	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98109	NULL
;	NULL
and	NULL
*Com-mittee	NULL
on	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
60637	NULL
Received	NULL
for	NULL
publication	NULL
April	NULL
6	NULL
,	NULL
2000	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
March	NULL
21	NULL
,	NULL
2001	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

These	NULL
studies	NULL
were	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
CA33084	NULL
,	NULL
CA18029	NULL
,	NULL
and	NULL
AI36613	NULL
.	NULL

R.F	NULL
.	NULL

was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
The	NULL
Benaroya	NULL
Foundation	NULL
Training	NULL
Grant	NULL
in	NULL
Immunology	NULL
.	NULL

2	NULL
Current	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Immunobiology	NULL
,	NULL
Yale	NULL
University	NULL
,	NULL
New	NULL
Haven	NULL
,	NULL
CT	NULL
06520	NULL
.	NULL

*	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Philip	NULL
D.	NULL
Greenberg	NULL
,	NULL
Program	NULL
in	NULL
Immunology	NULL
,	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
1100	NULL
Fairview	NULL
Avenue	NULL
North	NULL
D3-100	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98109	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
pgreen	NULL
@	NULL
u.washington.edu	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
require	NULL
costimulation	NULL
each	NULL
time	NULL
Ag	NULL
is	NULL
encountered	NULL
to	NULL
sustain	NULL
the	NULL
facility	NULL
for	NULL
IL-2	NULL
expression	NULL
.	NULL

Naive	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
2C	NULL
TCR-transgenic	NULL
mice	NULL
produced	NULL
IL-2	NULL
following	NULL
recognition	NULL
of	NULL
allogeneic	NULL
L*	NULL
target	NULL
cells	NULL
bearing	NULL
B7	NULL
costimulatory	NULL
molecules	NULL
(	NULL
14	NULL
)	NULL
,	NULL
but	NULL
lost	NULL
the	NULL
capacity	NULL
to	NULL
produce	NULL
IL-2	NULL
following	NULL
two	NULL
sequential	NULL
stimulations	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD28	NULL
costimulation	NULL
(	NULL
P.	NULL
Fields	NULL
,	NULL
unpublished	NULL
ob-servations	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
suggest	NULL
that	NULL
all	NULL
naive	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
may	NULL
initially	NULL
be	NULL
competent	NULL
to	NULL
produce	NULL
IL-2	NULL
,	NULL
but	NULL
lose	NULL
the	NULL
ability	NULL
to	NULL
sustain	NULL
growth	NULL
and	NULL
survival	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
not	NULL
receiving	NULL
the	NULL
necessary	NULL
costimulatory	NULL
signals	NULL
due	NULL
to	NULL
recognition	NULL
of	NULL
B7	NULL
~	NULL
targets	NULL
and/or	NULL
maturation	NULL
to	NULL
terminal	NULL
effector	NULL
cells	NULL
.	NULL

The	NULL
requirement	NULL
for	NULL
costimulation	NULL
for	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
can	NULL
be	NULL
circumvented	NULL
if	NULL
a	NULL
sufficiently	NULL
strong	NULL
signal	NULL
is	NULL
delivered	NULL
through	NULL
the	NULL
TCR	NULL
.	NULL

Effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
that	NULL
do	NULL
not	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
(	NULL
IL-2	NULL
)	NULL
can	NULL
be	NULL
triggered	NULL
to	NULL
produce	NULL
IL-2	NULL
by	NULL
cross-linking	NULL
the	NULL
TCR	NULL
with	NULL
anti-CD3	NULL
Abs	NULL
,	NULL
or	NULL
by	NULL
treatment	NULL
with	NULL
a	NULL
calcium	NULL
ionophore	NULL
,	NULL
such	NULL
as	NULL
ionomycin	NULL
,	NULL
in	NULL
conjunction	NULL
with	NULL
a	NULL
phorbol	NULL
ester	NULL
,	NULL
such	NULL
as	NULL
PMA	NULL
(	NULL
15	NULL
)	NULL
.	NULL

These	NULL
responses	NULL
to	NULL
such	NULL
nonphysi-ologic	NULL
stimuli	NULL
imply	NULL
that	NULL
the	NULL
inability	NULL
of	NULL
most	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
is	NULL
not	NULL
due	NULL
to	NULL
chromosomal	NULL
inaccessibility	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
,	NULL
but	NULL
might	NULL
instead	NULL
be	NULL
due	NULL
to	NULL
a	NULL
mechanism	NULL
operating	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
,	NULL
similar	NULL
to	NULL
what	NULL
has	NULL
been	NULL
found	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
block	NULL
to	NULL
IL-2	NULL
production	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
can	NULL
also	NULL
be	NULL
overcome	NULL
by	NULL
stimulation	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
share	NULL
several	NULL
additional	NULL
characteristics	NULL
with	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

IL-2~	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
can	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
and	NULL
supplemental	NULL
exogenous	NULL
IL-2	NULL
,	NULL
and	NULL
retain	NULL
the	NULL
capacity	NULL
to	NULL
produce	NULL
other	NULL
cytokines	NULL
such	NULL
as	NULL
IFN-y	NULL
.	NULL

Anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
can	NULL
proliferate	NULL
following	NULL
stimulation	NULL
if	NULL
exogenous	NULL
IL-2	NULL
is	NULL
provided	NULL
,	NULL
but	NULL
fail	NULL
to	NULL
expand	NULL
when	NULL
restimulated	NULL
with	NULL
Ag	NULL
even	NULL
if	NULL
costimulation	NULL
is	NULL
provided	NULL
because	NULL
of	NULL
a	NULL
specific	NULL
inability	NULL
to	NULL
produce	NULL
IL-2	NULL
,	NULL
while	NULL
retaining	NULL
the	NULL
capacity	NULL
to	NULL
produce	NULL
other	NULL
cytokines	NULL
such	NULL
as	NULL
IL-3	NULL
and	NULL
IFN-y	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
isolated	NULL
defect	NULL
in	NULL
IL-2	NULL
production	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
linked	NULL
to	NULL
reduced	NULL
levels	NULL
of	NULL
Fos/Jun	NULL
proteins	NULL
binding	NULL
at	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
19	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
to	NULL
negative	NULL
regulatory	NULL
factors	NULL
targeting	NULL
the	NULL
-150	NULL
and	NULL
-180	NULL
AP-1	NULL
sites	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

0022-1767/01/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
We	NULL
examined	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
better	NULL
understand	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
failure	NULL
of	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
.	NULL

Our	NULL
investigation	NULL
focused	NULL
on	NULL
the	NULL
AP-1	NULL
binding	NULL
sites	NULL
located	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
based	NULL
on	NULL
studies	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
suggesting	NULL
that	NULL
AP-1	NULL
is	NULL
the	NULL
target	NULL
of	NULL
clonal	NULL
anergy	NULL
.	NULL

AP-1	NULL
is	NULL
composed	NULL
of	NULL
homodimers	NULL
of	NULL
Jun	NULL
(	NULL
c-Jun	NULL
,	NULL
Jun	NULL
B	NULL
,	NULL
and	NULL
Jun	NULL
D	NULL
)	NULL
or	NULL
heterodimers	NULL
of	NULL
Jun	NULL
and	NULL
Fos	NULL
(	NULL
c-Fos	NULL
,	NULL
Fos	NULL
B	NULL
,	NULL
Fra-1	NULL
,	NULL
and	NULL
Fra-2	NULL
)	NULL
(	NULL
23	NULL
)	NULL
.	NULL

There	NULL
are	NULL
four	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
proximal	NULL
IL-2	NULL
promoter	NULL
that	NULL
can	NULL
bind	NULL
dimeric	NULL
combinations	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
members	NULL
.	NULL

Three	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
contain	NULL
nonconsensus	NULL
AP-1	NULL
motifs	NULL
adjacent	NULL
to	NULL
binding	NULL
sites	NULL
for	NULL
NFAT	NULL
,	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
,	NULL
*	NULL
and	NULL
OCT	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
both	NULL
elements	NULL
of	NULL
each	NULL
composite	NULL
site	NULL
must	NULL
be	NULL
occupied	NULL
for	NULL
transactivation	NULL
of	NULL
the	NULL
individual	NULL
enhancers	NULL
(	NULL
24-26	NULL
)	NULL
.	NULL

All	NULL
three	NULL
of	NULL
the	NULL
composite	NULL
AP-1	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
27	NULL
)	NULL
.	NULL

A	NULL
fourth	NULL
AP-1	NULL
site	NULL
at	NULL
-180	NULL
from	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
is	NULL
a	NULL
consensus	NULL
site	NULL
in	NULL
the	NULL
reverse	NULL
orientation	NULL
,	NULL
but	NULL
varies	NULL
from	NULL
a	NULL
consensus	NULL
AP-1	NULL
binding	NULL
site	NULL
by	NULL
one	NULL
base	NULL
pair	NULL
in	NULL
the	NULL
forward	NULL
orientation	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
-180	NULL
Ap-1	NULL
site	NULL
in	NULL
IL-2	NULL
promoter	NULL
regulation	NULL
has	NULL
not	NULL
previously	NULL
been	NULL
well	NULL
defined	NULL
.	NULL

However	NULL
,	NULL
recent	NULL
evidence	NULL
indicates	NULL
that	NULL
a	NULL
complex	NULL
of	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
and	NULL
cAMP	NULL
response	NULL
element	NULL
modulator	NULL
binds	NULL
to	NULL
this	NULL
site	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
22	NULL
)	NULL
,	NULL
perhaps	NULL
acting	NULL
to	NULL
repress	NULL
IL-2	NULL
gene	NULL
transcription	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
T	NULL
cell	NULL
clones	NULL
and	NULL
stimulator	NULL
lines	NULL
Four	NULL
H-2Lreactive	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
,	NULL
provided	NULL
by	NULL
Frank	NULL
Fitch	NULL
(	NULL
Uni-versity	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
,	NULL
were	NULL
chosen	NULL
for	NULL
evaluation	NULL
.	NULL

L3	NULL
and	NULL
DB45	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
do	NULL
not	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
antigenic	NULL
stimulation	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
and	NULL
Ld	NULL
8.6.1	NULL
and	NULL
2C	NULL
(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
(	NULL
IL-2	NULL
*	NULL
)	NULL
.	NULL

All	NULL
clones	NULL
were	NULL
restimulated	NULL
every	NULL
14	NULL
days	NULL
with	NULL
allogeneic	NULL
BALB/c	NULL
spleno-cytes	NULL
plus	NULL
12.5-25	NULL
U/ml	NULL
recombinant	NULL
human	NULL
IL-2	NULL
(	NULL
Chiron	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
-expressing	NULL
murine	NULL
mastocytoma	NULL
P815	NULL
,	NULL
also	NULL
obtained	NULL
from	NULL
Frank	NULL
Fitch	NULL
,	NULL
and	NULL
the	NULL
murine	NULL
BALB/c	NULL
tumor	NULL
,	NULL
LSTRA	NULL
,	NULL
maintained	NULL
in	NULL
our	NULL
laboratory	NULL
,	NULL
were	NULL
used	NULL
as	NULL
stimulator	NULL
cells	NULL
.	NULL

P815	NULL
was	NULL
transfected	NULL
with	NULL
both	NULL
B7-1	NULL
and	NULL
B7-2	NULL
to	NULL
provide	NULL
costimulation	NULL
,	NULL
and	NULL
LSTRA	NULL
naturally	NULL
expresses	NULL
both	NULL
B7-1	NULL
and	NULL
B7-2	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640-HEPES	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
HyClone	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
4	NULL
mM	NULL
L-glutamine	NULL
,	NULL
50	NULL
U/ml	NULL
penicillin	NULL
,	NULL
50	NULL
pg/ml	NULL
streptomycin	NULL
,	NULL
and	NULL
5	NULL
X	NULL
10~°	NULL
M	NULL
2-ME	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
cell	NULL
surface	NULL
molecules	NULL
on	NULL
T	NULL
cell	NULL
clones	NULL
Cells	NULL
were	NULL
analyzed	NULL
with	NULL
a	NULL
FACSCalibur	NULL
flow	NULL
cytometer	NULL
using	NULL
CellQuest	NULL
software	NULL
(	NULL
BD	NULL
Biosciences	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
.	NULL
)	NULL

.	NULL

All	NULL
Abs	NULL
were	NULL
purchased	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
unless	NULL
otherwise	NULL
noted	NULL
.	NULL

CD3	NULL
and	NULL
CD8	NULL
expression	NULL
were	NULL
evaluated	NULL
with	NULL
PE-conjugated	NULL
anti-CD3	NULL
(	NULL
145-2011	NULL
)	NULL
and	NULL
PE-conjugated	NULL
anti-CD8	NULL
«	NULL
(	NULL
53-6.7	NULL
)	NULL
.	NULL

PE-conjugated	NULL
anti-CD4	NULL
(	NULL
GK1.5	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
for	NULL
nonspecific	NULL
staining	NULL
.	NULL

CD28	NULL
expression	NULL
was	NULL
evaluated	NULL
with	NULL
mAb	NULL
37.51	NULL
,	NULL
followed	NULL
by	NULL
FITC-labeled	NULL
rabbit	NULL
anti-hamster	NULL
IgG	NULL
(	NULL
Jack-son	NULL
ImmunoResearch	NULL
,	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
using	NULL
hamster	NULL
IgG	NULL
anti-keyhole	NULL
limpet	NULL
hemocyanin	NULL
Ab	NULL
Ha4/8	NULL
as	NULL
an	NULL
isotype	NULL
control	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
cytokine	NULL
gene	NULL
transcription	NULL
T	NULL
cell	NULL
clones	NULL
were	NULL
cultured	NULL
at	NULL
37°C	NULL
for	NULL
6	NULL
h	NULL
in	NULL
six-well	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
an	NULL
equal	NULL
number	NULL
of	NULL
stimulator	NULL
cells	NULL
,	NULL
plate-bound	NULL
anti-CD3	NULL
(	NULL
2C11	NULL
)	NULL
at	NULL
1	NULL
pg/ml	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
(	NULL
37.51	NULL
)	NULL
at	NULL
1	NULL
ug/ml	NULL
each	NULL
,	NULL
or	NULL
10	NULL
ng/ml	NULL
PMA	NULL
plus	NULL
1	NULL
pM	NULL
ionomycin	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
,	NULL
RNA	NULL
was	NULL
extracted	NULL
with	NULL
RNAgents	NULL
Total	NULL
RNA	NULL
Isolation	NULL
kit	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
,	NULL
and	NULL
reverse	NULL
transcribed	NULL
into	NULL
cDNA	NULL
using	NULL
Superscript	NULL
II	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithers-burg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
was	NULL
amplified	NULL
with	NULL
primers	NULL
specific	NULL
for	NULL
murine	NULL
IL-2	NULL
or	NULL
IFN-y	NULL
,	NULL
and	NULL
all	NULL
reactions	NULL
included	NULL
B-actin	NULL
primers	NULL
to	NULL
control	NULL
for	NULL
cDNA	NULL
input	NULL
.	NULL

Forward	NULL
(	NULL
F	NULL
)	NULL
and	NULL
reverse	NULL
(	NULL
R	NULL
)	NULL
primers	NULL
were	NULL
generated	NULL
by	NULL
Life	NULL
Technol-	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CD28RE	NULL
,	NULL
CD28	NULL
response	NULL
element	NULL
;	NULL
B-gal	NULL
,	NULL
B-ga-lactosidase	NULL
;	NULL
CPS	NULL
,	NULL
counts	NULL
per	NULL
second	NULL
;	NULL
CREB	NULL
,	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
;	NULL
ERK	NULL
,	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
;	NULL
FRK	NULL
,	NULL
Fos	NULL
regulating	NULL
kinase	NULL
;	NULL
JNK	NULL
,	NULL
Jun	NULL
amino-terminal	NULL
kinase	NULL
;	NULL
PCR	NULL
SOEing	NULL
,	NULL
PCR	NULL
Splice	NULL
Overlap	NULL
Extension	NULL
technique	NULL
;	NULL
F	NULL
,	NULL
forward	NULL
;	NULL
R	NULL
,	NULL
reverse	NULL
.	NULL

6531	NULL
ogies	NULL
and	NULL
paired	NULL
as	NULL
follows	NULL
:	NULL
IL-2	NULL
``	NULL
:	NULL
CCTGCAGGCATGTACAGCATG	NULL
+	NULL
IL-2	NULL
``	NULL
:	NULL
GAGGTACATAGTTATTGAGGGC	NULL
,	NULL
yielding	NULL
a	NULL
510-bp	NULL
product	NULL
from	NULL
the	NULL
IL-2	NULL
gene	NULL
that	NULL
spans	NULL
exon/intron	NULL
boundaries	NULL
,	NULL
IFN-y	NULL
:	NULL
GCTCTGAGA	NULL
CAATGAACGCTA	NULL
+	NULL
IFN-y®	NULL
:	NULL
CGAATCAGCAGCGACTCCTIT	NULL
,	NULL
yielding	NULL
a	NULL
475-bp	NULL
product	NULL
from	NULL
the	NULL
ZIFN-y	NULL
gene	NULL
that	NULL
spans	NULL
exon/intron	NULL
boundaries	NULL
,	NULL
and	NULL
B-actin	NULL
``	NULL
:	NULL
GACGGGGTCACCCACACTGTGCCCATCTA	NULL
+	NULL
B-actin®	NULL
:	NULL
GAAGTCTAGAGCAACATAGCACAGCITTCTC	NULL
,	NULL
yielding	NULL
a	NULL
200-bp	NULL
prod-uct	NULL
.	NULL

PCR	NULL
was	NULL
repeated	NULL
for	NULL
25	NULL
cycles	NULL
for	NULL
IFN-y	NULL
and	NULL
35	NULL
cycles	NULL
for	NULL
IL-2	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
on	NULL
the	NULL
DeltaCycler	NULL
II	NULL
(	NULL
Ericomp	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
resolved	NULL
on	NULL
1.5	NULL
%	NULL
agarose	NULL
gels	NULL
and	NULL
visualized	NULL
by	NULL
ethidium	NULL
bromide	NULL
staining	NULL
.	NULL

Reporter	NULL
gene	NULL
constructs	NULL
The	NULL
LacZH	NULL
constructs	NULL
containing	NULL
multimers	NULL
of	NULL
IL-2	NULL
promoter	NULL
enhancer	NULL
elements	NULL
driving	NULL
expression	NULL
of	NULL
the	NULL
Escherichia	NULL
coli	NULL
lacZ	NULL
reporter	NULL
gene	NULL
,	NULL
with	NULL
the	NULL
hygromycin	NULL
resistance	NULL
gene	NULL
(	NULL
H	NULL
)	NULL
for	NULL
selection	NULL
of	NULL
stable	NULL
transfectants	NULL
have	NULL
been	NULL
described	NULL
elsewhere	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
IL-2-LacZH	NULL
contains	NULL
-326	NULL
to	NULL
+47	NULL
of	NULL
the	NULL
proximal	NULL
human	NULL
IL-2	NULL
promoter	NULL
;	NULL
NFAT/AP-1-LacZH	NULL
contains	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NFAT/AP-1	NULL
binding	NULL
site	NULL
(	NULL
-286	NULL
to	NULL
-257	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
(	NULL
-72	NULL
to	NULL
+47	NULL
)	NULL
encoding	NULL
the	NULL
TATA	NULL
box	NULL
and	NULL
transcriptional	NULL
start	NULL
site	NULL
;	NULL
OCT/AP-1-LacZH	NULL
contains	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
OCT/AP-1	NULL
binding	NULL
site	NULL
(	NULL
-93	NULL
to	NULL
-65	NULL
)	NULL
attached	NULL
to	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
;	NULL
and	NULL
CD28RE/AP-1-LacZH	NULL
contains	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
CD28RE/	NULL
AP-1	NULL
binding	NULL
region	NULL
(	NULL
-	NULL
159	NULL
to	NULL
-134	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
.	NULL

A	NULL
consensus	NULL
AP-1	NULL
reporter	NULL
gene	NULL
construct	NULL
was	NULL
generated	NULL
using	NULL
oligo-nucleotides	NULL
(	NULL
oligo	NULL
)	NULL
representing	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
human	NULL
metallothionein	NULL
gene	NULL
(	NULL
33	NULL
)	NULL
:	NULL
tegaCGCTTGATGACTCAGCCGGAA	NULL
and	NULL
tc	NULL
gaTTCCGGCTGAGTCATCAAGCG	NULL
(	NULL
AP-1	NULL
binding	NULL
site	NULL
underlined	NULL
,	NULL
XhoI	NULL
overlap	NULL
bases	NULL
in	NULL
lower	NULL
case	NULL
italics	NULL
)	NULL
.	NULL

Oligos	NULL
were	NULL
annealed	NULL
and	NULL
ligated	NULL
into	NULL
LacZH	NULL
containing	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
.	NULL

A	NULL
plasmid	NULL
with	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
AP-1	NULL
consensus	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
forward	NULL
orientation	NULL
and	NULL
one	NULL
copy	NULL
in	NULL
the	NULL
reverse	NULL
orientation	NULL
was	NULL
selected	NULL
for	NULL
transfection	NULL
studies	NULL
.	NULL

Fluorescent	NULL
sequencing	NULL
was	NULL
performed	NULL
on	NULL
an	NULL
Applied	NULL
Biosystems	NULL
Fluorescent	NULL
Sequencer	NULL
using	NULL
Taq	NULL
Dye	NULL
Terminator	NULL
reagents	NULL
(	NULL
Applied	NULL
Biosystems	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Mutations	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
were	NULL
accomplished	NULL
using	NULL
the	NULL
PCR	NULL
Splice	NULL
Overlap	NULL
Extension	NULL
technique	NULL
(	NULL
PCR	NULL
SOEing	NULL
)	NULL
(	NULL
34	NULL
)	NULL
,	NULL
with	NULL
IL-2-LacZH	NULL
serving	NULL
as	NULL
a	NULL
template	NULL
.	NULL

External	NULL
primers	NULL
were	NULL
the	NULL
same	NULL
for	NULL
all	NULL
PCR	NULL
SOEing	NULL
reactions	NULL
.	NULL

The	NULL
external	NULL
forward	NULL
primer	NULL
(	NULL
EX	NULL
``	NULL
)	NULL
ATCGATGTTTTCTGAGT	NULL
TACTT	NULL
is	NULL
complementary	NULL
to	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
320-bp	NULL
IL-2	NULL
promoter	NULL
,	NULL
and	NULL
the	NULL
external	NULL
reverse	NULL
primer	NULL
(	NULL
EX®	NULL
)	NULL
TTCCCAGTCACGACGTTGTA	NULL
is	NULL
complementary	NULL
to	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
lacZ	NULL
gene	NULL
.	NULL

In	NULL
the	NULL
internal	NULL
primers	NULL
listed	NULL
below	NULL
,	NULL
the	NULL
binding	NULL
sites	NULL
are	NULL
underlined	NULL
and	NULL
mutations	NULL
are	NULL
in	NULL
bold	NULL
type	NULL
.	NULL

The	NULL
-180	NULL
AP-1	NULL
site	NULL
was	NULL
mutated	NULL
to	NULL
a	NULL
nonbinding	NULL
site	NULL
by	NULL
pairing	NULL
EX	NULL
``	NULL
with	NULL
the	NULL
-180	NULL
AP-1	NULL
Null	NULL
reverse	NULL
primer	NULL
CCAAAGACTGCAAGAATGGATG	NULL
TAG	NULL
in	NULL
one	NULL
PCR	NULL
,	NULL
and	NULL
EX	NULL
``	NULL
with	NULL
the	NULL
-180	NULL
AP-1	NULL
Null	NULL
forward	NULL
primer	NULL
CTACATCCATTCTTGCAGTCTTTGG	NULL
in	NULL
a	NULL
separate	NULL
PCR	NULL
.	NULL

The	NULL
-150	NULL
AP-1	NULL
site	NULL
was	NULL
replaced	NULL
with	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
by	NULL
pairing	NULL
EX	NULL
``	NULL
and	NULL
the	NULL
-150	NULL
AP-1	NULL
consensus	NULL
reverse	NULL
primer	NULL
CTCTTCTGATGAGTCATTG	NULL
GAATTTC	NULL
in	NULL
one	NULL
PCR	NULL
,	NULL
and	NULL
EX®	NULL
with	NULL
the	NULL
-150	NULL
AP-1	NULL
consensus	NULL
forward	NULL
primer	NULL
GAAATTCCAATGACTCATCAGAGAG	NULL
in	NULL
a	NULL
separate	NULL
PCR	NULL
.	NULL

A	NULL
composite	NULL
CD28RE/AP-1	NULL
consensus	NULL
site	NULL
was	NULL
added	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
pairing	NULL
EX	NULL
``	NULL
with	NULL
the	NULL
CD28RE/AP-1	NULL
consensus	NULL
reverse	NULL
primer	NULL
ATTTCTT	NULL
TAAACCCCCAAAGACTGAGTCA	NULL
,	NULL
and	NULL
then	NULL
EX	NULL
``	NULL
with	NULL
the	NULL
CD28RE/AP-1	NULL
consensus	NULL
forward	NULL
primer	NULL
TTTGGGGGTTTAAAGAAATTCCAAT	NULL
GACTCA	NULL
.	NULL

The	NULL
products	NULL
from	NULL
each	NULL
of	NULL
the	NULL
sets	NULL
of	NULL
PCR	NULL
were	NULL
combined	NULL
and	NULL
used	NULL
as	NULL
overlapping	NULL
templates	NULL
in	NULL
PCR	NULL
SOEing	NULL
reactions	NULL
with	NULL
external	NULL
primers	NULL
to	NULL
generate	NULL
the	NULL
IL-2	NULL
promoter	NULL
with	NULL
the	NULL
designated	NULL
mutations	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

The	NULL
fidelity	NULL
of	NULL
the	NULL
mutations	NULL
was	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

Stable	NULL
transfection	NULL
of	NULL
murine	NULL
T	NULL
cell	NULL
clones	NULL
and	NULL
P815	NULL
T	NULL
cell	NULL
clones	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
at	NULL
250	NULL
mV	NULL
,	NULL
940	NULL
F	NULL
(	NULL
Pro-genetor	NULL
II	NULL
;	NULL
Hoefer	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
6	NULL
days	NULL
after	NULL
antigenic	NULL
stimulation	NULL
with	NULL
irradiated	NULL
BALB/c	NULL
splenocytes	NULL
.	NULL

All	NULL
reporter	NULL
gene	NULL
plasmids	NULL
were	NULL
lin-earized	NULL
5	NULL
'	NULL
of	NULL
the	NULL
promoter	NULL
of	NULL
interest	NULL
.	NULL

Electroporated	NULL
cells	NULL
were	NULL
selected	NULL
for	NULL
2-3	NULL
wk	NULL
in	NULL
medium	NULL
containing	NULL
0.25	NULL
mg/ml	NULL
hygromycin	NULL
.	NULL

Aliquots	NULL
of	NULL
the	NULL
hygromycin-resistant	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
10	NULL
ng/ml	NULL
PMA	NULL
plus	NULL
1	NULL
M	NULL
ionomycin	NULL
for	NULL
3	NULL
h	NULL
,	NULL
then	NULL
assayed	NULL
histochemically	NULL
for	NULL
B-galactosidase	NULL
(	NULL
B-gal	NULL
)	NULL
expression	NULL
(	NULL
35	NULL
)	NULL
.	NULL

It	NULL
was	NULL
necessary	NULL
to	NULL
subclone	NULL
the	NULL
majority	NULL
of	NULL
transfected	NULL
lines	NULL
to	NULL
enrich	NULL
for	NULL
B-gal-expressing	NULL
cells	NULL
.	NULL

B-gal*	NULL
lines	NULL
were	NULL
sub-cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
in	NULL
96-well	NULL
plates	NULL
,	NULL
and	NULL
only	NULL
transfectants	NULL
that	NULL
expressed	NULL
negligible	NULL
B-gal	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
were	NULL
selected	NULL
.	NULL

cDNAs	NULL
encoding	NULL
murine	NULL
B7-1	NULL
and	NULL
B7-2	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
eukaryotic	NULL
vectors	NULL
pNA	NULL
'	NULL
and	NULL
pHA	NULL
'	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Both	NULL
constructs	NULL
were	NULL
linearized	NULL
,	NULL
then	NULL
transfected	NULL
into	NULL
P815	NULL
cells	NULL
via	NULL
electroporation	NULL
(	NULL
250	NULL
mV	NULL
,	NULL
940	NULL
uF	NULL
)	NULL
.	NULL

Electroporated	NULL
cells	NULL
were	NULL
selected	NULL
with	NULL
0.5	NULL
mg/ml	NULL
G418	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6532	NULL
TRANSCRIPTIONAL	NULL
BLOCK	NULL
AT	NULL
-150	NULL
AP-1	NULL
SITE	NULL
IN	NULL
CD	NULL
#	NULL
8	NULL
#	NULL
*	NULL
T	NULL
CELLS	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
0.25	NULL
mg/ml	NULL
hygromycin	NULL
B	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianap-olis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Antibiotic-resistant	NULL
cells	NULL
were	NULL
screened	NULL
for	NULL
both	NULL
B7-1	NULL
and	NULL
B7-2	NULL
expression	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
FITC-coupled	NULL
anti-B7-1	NULL
(	NULL
1G10	NULL
)	NULL
and	NULL
anti-B7-2	NULL
(	NULL
GL-1	NULL
)	NULL
.	NULL

Positive	NULL
cells	NULL
were	NULL
sorted	NULL
into	NULL
96-well	NULL
culture	NULL
plates	NULL
(	NULL
Costar	NULL
)	NULL
.	NULL

Surface	NULL
expression	NULL
of	NULL
B7-1	NULL
and	NULL
B7-2	NULL
on	NULL
subclones	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
and	NULL
a	NULL
subclone	NULL
expressing	NULL
matched	NULL
high	NULL
levels	NULL
of	NULL
B7-1	NULL
and	NULL
B7-2	NULL
was	NULL
selected	NULL
for	NULL
use	NULL
as	NULL
a	NULL
stimulator	NULL
cell	NULL
line	NULL
.	NULL

Transfected	NULL
P815	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
medium	NULL
with	NULL
0.5	NULL
mg/ml	NULL
G418	NULL
and	NULL
0.25	NULL
mg/ml	NULL
hygromycin	NULL
B	NULL
,	NULL
and	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
periodically	NULL
to	NULL
verify	NULL
stable	NULL
B7-1	NULL
and	NULL
B7-2	NULL
expression	NULL
.	NULL

Chemiluminescent	NULL
assay	NULL
for	NULL
quantitation	NULL
of	NULL
B-gal	NULL
activity	NULL
$	NULL
B-gal	NULL
activity	NULL
was	NULL
measured	NULL
using	NULL
the	NULL
chemiluminescent	NULL
substrate	NULL
Galac-ton-Star	NULL
(	NULL
Tropix	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
(	NULL
1.25	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
plated	NULL
in	NULL
triplicate	NULL
in	NULL
96-well	NULL
plates	NULL
for	NULL
6	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
an	NULL
equal	NULL
number	NULL
of	NULL
P815	NULL
stimulator	NULL
cells	NULL
,	NULL
or	NULL
10	NULL
ng/ml	NULL
PMA	NULL
plus	NULL
1	NULL
M	NULL
ionomycin	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
lysed	NULL
with	NULL
buffer	NULL
provided	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
with	NULL
chemiluminescent	NULL
substrate	NULL
for	NULL
1	NULL
h	NULL
in	NULL
Dynex	NULL
Mi-croFLUOR	NULL
black	NULL
96-well	NULL
microplates	NULL
(	NULL
Dynex	NULL
Technologies	NULL
,	NULL
Chantilly	NULL
,	NULL
VA	NULL
)	NULL
.	NULL

Light	NULL
output	NULL
was	NULL
measured	NULL
using	NULL
the	NULL
Single	NULL
Photon	NULL
Count	NULL
mode	NULL
at	NULL
24°C	NULL
for	NULL
1.2	NULL
s/well	NULL
on	NULL
a	NULL
Packard	NULL
Top	NULL
Count	NULL
microplate	NULL
luminometer	NULL
(	NULL
Packard	NULL
,	NULL
Meriden	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

Due	NULL
to	NULL
variations	NULL
in	NULL
B-gal	NULL
activity	NULL
among	NULL
subclones	NULL
possibly	NULL
resulting	NULL
from	NULL
a	NULL
variable	NULL
number	NULL
of	NULL
integrated	NULL
transgenes	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
B-gal	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
detected	NULL
in	NULL
unstimulated	NULL
cells	NULL
for	NULL
a	NULL
panel	NULL
of	NULL
six	NULL
subclones	NULL
from	NULL
each	NULL
transfectant	NULL
.	NULL

The	NULL
subclones	NULL
representing	NULL
the	NULL
mean	NULL
level	NULL
of	NULL
-gal	NULL
induction	NULL
for	NULL
each	NULL
stimulation	NULL
condition	NULL
are	NULL
shown	NULL
as	NULL
the	NULL
representative	NULL
transfectants	NULL
(	NULL
see	NULL
Figs	NULL
.	NULL

4-	NULL
6	NULL
)	NULL
.	NULL

Results	NULL
IL-2~	NULL
and	NULL
IL-2	NULL
``	NULL
CD8	NULL
T	NULL
cell	NULL
clones	NULL
express	NULL
comparable	NULL
levels	NULL
of	NULL
CD3	NULL
,	NULL
CD8	NULL
,	NULL
and	NULL
CD28	NULL
One	NULL
possible	NULL
explanation	NULL
for	NULL
the	NULL
inability	NULL
of	NULL
some	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
is	NULL
decreased	NULL
signal	NULL
strength	NULL
due	NULL
to	NULL
down-regulation	NULL
of	NULL
critical	NULL
signaling	NULL
molecules	NULL
.	NULL

Therefore	NULL
,	NULL
surface	NULL
expression	NULL
of	NULL
CD3	NULL
,	NULL
CD8	NULL
,	NULL
and	NULL
CD28	NULL
on	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
was	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
IL-2~	NULL
clones	NULL
,	NULL
L3	NULL
and	NULL
DB45	NULL
,	NULL
and	NULL
the	NULL
IL-2*	NULL
clones	NULL
,	NULL
2C	NULL
and	NULL
Ld	NULL
8.6.1	NULL
,	NULL
expressed	NULL
approximately	NULL
equivalent	NULL
levels	NULL
of	NULL
CD3	NULL
and	NULL
CD8	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

CD28	NULL
was	NULL
expressed	NULL
at	NULL
the	NULL
highest	NULL
levels	NULL
on	NULL
L3	NULL
,	NULL
and	NULL
was	NULL
approximately	NULL
equivalent	NULL
on	NULL
DB45	NULL
and	NULL
2C	NULL
,	NULL
but	NULL
slightly	NULL
lower	NULL
on	NULL
Ld	NULL
8.6.1	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
reduction	NULL
of	NULL
CD3	NULL
,	NULL
CD8	NULL
,	NULL
or	NULL
CD28	NULL
on	NULL
L3	NULL
and	NULL
DB45	NULL
did	NULL
not	NULL
account	NULL
for	NULL
the	NULL
inability	NULL
of	NULL
these	NULL
clones	NULL
to	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
.	NULL

IL-2~	NULL
CD8¢	NULL
T	NULL
cells	NULL
do	NULL
not	NULL
transcribe	NULL
IL-2	NULL
mRNA	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
Transcription	NULL
of	NULL
the	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
genes	NULL
was	NULL
assessed	NULL
under	NULL
varying	NULL
conditions	NULL
:	NULL
either	NULL
medium	NULL
alone	NULL
,	NULL
or	NULL
after	NULL
stimulation	NULL
with	NULL
LSTRA	NULL
,	NULL
P815	NULL
,	NULL
P815/B7-1	NULL
+	NULL
2	NULL
transfectants	NULL
,	NULL
plate-bound	NULL
anti-CD3	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
.	NULL

All	NULL
clones	NULL
were	NULL
assessed	NULL
6	NULL
h	NULL
after	NULL
stimulation	NULL
following	NULL
a	NULL
rest	NULL
period	NULL
of	NULL
10	NULL
days	NULL
from	NULL
the	NULL
previous	NULL
stimulation	NULL
.	NULL

IFN-y	NULL
mRNA	NULL
was	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
all	NULL
stimuli	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
cells	NULL
were	NULL
activated	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

No	NULL
baseline	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
was	NULL
detectable	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Following	NULL
stimulation	NULL
with	NULL
plate-bound	NULL
anti-CD3	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
IL-2	NULL
mRNA	NULL
was	NULL
transcribed	NULL
by	NULL
all	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

In	NULL
response	NULL
to	NULL
allogeneic	NULL
stimulation	NULL
with	NULL
LSTRA	NULL
,	NULL
P815	NULL
cells	NULL
,	NULL
or	NULL
P815/B7-1	NULL
+	NULL
2	NULL
transfectants	NULL
,	NULL
the	NULL
IL-2	NULL
*	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
2C	NULL
and	NULL
Ld	NULL
8.6.1	NULL
transcribed	NULL
IL-2	NULL
mRNA	NULL
,	NULL
whereas	NULL
the	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
L3	NULL
and	NULL
DB45	NULL
did	NULL
not	NULL
transcribe	NULL
detectable	NULL
IL-2	NULL
mRNA	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
restriction	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
subsets	NULL
is	NULL
controlled	NULL
at	NULL
least	NULL
in	NULL
part	NULL
at	NULL
the	NULL
level	NULL
of	NULL
mRNA	NULL
transcription	NULL
and/or	NULL
stability	NULL
.	NULL

A	NULL
B	NULL
C	NULL
L3	NULL
°	NULL
.	NULL

aust	NULL
ant	NULL
G9	NULL
(	NULL
84	NULL
19	NULL
ao	NULL
!	NULL

ao	NULL
``	NULL
10°	NULL
40	NULL
%	NULL
10°	NULL
ao	NULL
!	NULL

102	NULL
10	NULL
%	NULL
104	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10	NULL
8	NULL
sd	NULL
DB45	NULL
O0	NULL
,	NULL
TUTU	NULL
T3	NULL
Taus	NULL
an	NULL
!	NULL

aot	NULL
50°	NULL
aot	NULL
10°	NULL
ao	NULL
!	NULL

102	NULL
10°	NULL
10	NULL
%	NULL
10°	NULL
ao	NULL
``	NULL
10°	NULL
10°	NULL
104	NULL
10°	NULL
10	NULL
``	NULL
10	NULL
``	NULL
10°	NULL
10	NULL
8	NULL
&	NULL
2C	NULL
°	NULL
.	NULL

.	NULL

1	NULL
vG	NULL
te	NULL
(	NULL
ha	NULL
10°	NULL
ao	NULL
!	NULL

40f	NULL
aot	NULL
10	NULL
%	NULL
40°	NULL
ao	NULL
``	NULL
ao	NULL
``	NULL
40°	NULL
10	NULL
%	NULL
10°	NULL
ao	NULL
``	NULL
ao	NULL
``	NULL
10	NULL
``	NULL
do	NULL
o	NULL
FL2H	NULL
a	NULL
Ld	NULL
T	NULL
8.6.1	NULL
o	NULL
.	NULL

k	NULL
I	NULL
10°	NULL
do	NULL
``	NULL
aot	NULL
10	NULL
%	NULL
10	NULL
%	NULL
40°	NULL
ao	NULL
``	NULL
102	NULL
10°	NULL
10	NULL
%	NULL
10°	NULL
40	NULL
``	NULL
10	NULL
``	NULL
10°	NULL
10+	NULL
CD3	NULL
CD8	NULL
CD28	NULL
Mean	NULL
Fluorescence	NULL
Intensity	NULL
FIGURE	NULL
1	NULL
.	NULL

Comparable	NULL
expression	NULL
of	NULL
CD3	NULL
,	NULL
CD8	NULL
,	NULL
and	NULL
CD28	NULL
on	NULL
IL-2~	NULL
and	NULL
IL-2*	NULL
CD8*	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

T	NULL
cell	NULL
clones	NULL
were	NULL
stained	NULL
for	NULL
CD3	NULL
(	NULL
4	NULL
)	NULL
,	NULL
CD8	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
CD28	NULL
(	NULL
C	NULL
)	NULL
expression	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
shaded	NULL
curve	NULL
represents	NULL
unstained	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
unshaded	NULL
curve	NULL
represents	NULL
staining	NULL
with	NULL
the	NULL
labeled	NULL
Ab	NULL
.	NULL

The	NULL
proximal	NULL
IL-2	NULL
promoter	NULL
is	NULL
not	NULL
transactivated	NULL
in	NULL
IL-2	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
Transactivation	NULL
of	NULL
the	NULL
proximal	NULL
IL-2	NULL
promoter	NULL
was	NULL
evaluated	NULL
in	NULL
response	NULL
to	NULL
varying	NULL
stimuli	NULL
.	NULL

The	NULL
proximal	NULL
IL-2	NULL
promoter-LacZH	NULL
reporter	NULL
gene	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
was	NULL
stably	NULL
transfected	NULL
into	NULL
the	NULL
IL-2~	NULL
CD8	NULL
*	NULL
clones	NULL
L3	NULL
and	NULL
DB45	NULL
,	NULL
and	NULL
into	NULL
the	NULL
IL-2	NULL
*	NULL
CD8	NULL
*	NULL
clone	NULL
2C	NULL
,	NULL
which	NULL
most	NULL
closely	NULL
matched	NULL
the	NULL
surface	NULL
phenotype	NULL
of	NULL
the	NULL
IL-2~	NULL
CD8	NULL
*	NULL
clones	NULL
.	NULL

Ld	NULL
8.6.1	NULL
was	NULL
not	NULL
used	NULL
in	NULL
reporter	NULL
gene	NULL
analyses	NULL
due	NULL
to	NULL
variable	NULL
stability	NULL
of	NULL
transgenes	NULL
in	NULL
this	NULL
clone	NULL
.	NULL

Reporter	NULL
gene	NULL
expression	NULL
was	NULL
detected	NULL
in	NULL
both	NULL
L3	NULL
and	NULL
DB45	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
but	NULL
no	NULL
significant	NULL
activity	NULL
was	NULL
observed	NULL
after	NULL
6	NULL
h	NULL
in	NULL
response	NULL
to	NULL
antigenic	NULL
stimulation	NULL
with	NULL
P815	NULL
or	NULL
P85/	NULL
B7-1	NULL
+	NULL
2	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
IL-2	NULL
``	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clone	NULL
2C	NULL
transactivated	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
P815	NULL
,	NULL
and	NULL
costimulation	NULL
with	NULL
B7-1	NULL
and	NULL
B7-2	NULL
enhanced	NULL
transactivation	NULL
compared	NULL
with	NULL
stimulation	NULL
with	NULL
P815	NULL
alone	NULL
.	NULL

Analysis	NULL
of	NULL
a	NULL
panel	NULL
of	NULL
L3	NULL
and	NULL
DB45	NULL
subclones	NULL
failed	NULL
to	NULL
detect	NULL
any	NULL
cells	NULL
capable	NULL
of	NULL
transactivating	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
,	NULL
or	NULL
Ag	NULL
plus	NULL
costimulation	NULL
.	NULL

Disruption	NULL
of	NULL
the	NULL
potentially	NULL
inhibitory	NULL
-180	NULL
AP-1	NULL
binding	NULL
site	NULL
does	NULL
not	NULL
restore	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
We	NULL
evaluated	NULL
whether	NULL
a	NULL
negative	NULL
regulatory	NULL
factor	NULL
similar	NULL
to	NULL
that	NULL
identified	NULL
in	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
played	NULL
a	NULL
role	NULL
in	NULL
negatively	NULL
regulating	NULL
IL-2	NULL
promoter	NULL
transactivation	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
removing	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
putative	NULL
inhibitor	NULL
.	NULL

The	NULL
-180	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
was	NULL
converted	NULL
to	NULL
a	NULL
nonbinding	NULL
site	NULL
by	NULL
mutating	NULL
the	NULL
TCAGTCA	NULL
AP-1	NULL
motif	NULL
to	NULL
TCTTGCA	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
,	NULL
because	NULL
an	NULL
identical	NULL
3-bp	NULL
mutation	NULL
restored	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
cells	NULL
(	NULL
21	NULL
)	NULL
.	NULL

In	NULL
L3	NULL
and	NULL
DB45	NULL
transfectants	NULL
,	NULL
the	NULL
-180	NULL
AP-1	NULL
null	NULL
version	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
was	NULL
very	NULL
weakly	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

This	NULL
reduced	NULL
activity	NULL
in	NULL
comparison	NULL
to	NULL
the	NULL
native	NULL
IL-2	NULL
promoter	NULL
suggested	NULL
a	NULL
potential	NULL
positive	NULL
rather	NULL
than	NULL
negative	NULL
contribution	NULL
from	NULL
this	NULL
site	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

No	NULL
significant	NULL
response	NULL
was	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A.	NULL
IFNy	NULL
B.	NULL
IL-2	NULL
yMW1234567	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
MW	NULL
L3	NULL
-IMy	NULL
[	NULL
-ACTN	NULL
peas	NULL
-IMy	NULL
pan	NULL
oi	NULL
2C	NULL
IFNy	NULL
frACTN	NULL
Ld	NULL
8.6.1	NULL
[	NULL
-ACTN	NULL
FIGURE	NULL
2	NULL
.	NULL

Differential	NULL
transcription	NULL
of	NULL
IL-2	NULL
mRNA	NULL
in	NULL
IL-2	NULL
and	NULL
IL-2*	NULL
CD8*	NULL
T	NULL
cell	NULL
clones	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
h	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
Zane	NULL
7	NULL
)	NULL
,	NULL
LSTRA	NULL
(	NULL
2	NULL
)	NULL
,	NULL
P815	NULL
(	NULL
3	NULL
)	NULL
,	NULL
P815/	NULL
B7-1	NULL
+	NULL
2	NULL
(	NULL
4	NULL
)	NULL
,	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
5	NULL
)	NULL
,	NULL
anti-CD3	NULL
(	NULL
6	NULL
)	NULL
,	NULL
or	NULL
anti-CD3	NULL
+	NULL
anti-CD28	NULL
(	NULL
7	NULL
)	NULL
.	NULL

MW	NULL
,	NULL
A	NULL
100-bp	NULL
molecular	NULL
weight	NULL
ladder	NULL
(	NULL
Life	NULL
Technolo-gies	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
harvested	NULL
and	NULL
cDNA	NULL
made	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

A	NULL
475-bp	NULL
product	NULL
was	NULL
amplified	NULL
by	NULL
RT-PCR	NULL
from	NULL
IFN-y	NULL
cDNA	NULL
(	NULL
A	NULL
)	NULL
,	NULL
and	NULL
a	NULL
510-bp	NULL
product	NULL
was	NULL
amplified	NULL
from	NULL
IL-2	NULL
cDNA	NULL
(	NULL
B	NULL
)	NULL
.	NULL

A	NULL
200-bp	NULL
fragment	NULL
of	NULL
the	NULL
B-actin	NULL
gene	NULL
was	NULL
amplified	NULL
in	NULL
all	NULL
reactions	NULL
as	NULL
a	NULL
control	NULL
for	NULL
cDNA	NULL
input	NULL
.	NULL

observed	NULL
in	NULL
L3	NULL
or	NULL
DB45	NULL
transfectants	NULL
following	NULL
stimulation	NULL
with	NULL
Ag	NULL
or	NULL
Ag	NULL
plus	NULL
costimulation	NULL
.	NULL

Analysis	NULL
of	NULL
multiple	NULL
subclones	NULL
of	NULL
L3	NULL
and	NULL
DB45	NULL
confirmed	NULL
that	NULL
the	NULL
-180	NULL
AP-1	NULL
mutation	NULL
severely	NULL
reduced	NULL
IL-2	NULL
promoter	NULL
activity	NULL
.	NULL

IL-2	NULL
``	NULL
2C	NULL
transfectants	NULL
bearing	NULL
the	NULL
-180	NULL
AP-1	NULL
null	NULL
mutation	NULL
exhibited	NULL
marginal	NULL
promoter	NULL
activity	NULL
compared	NULL
with	NULL
the	NULL
native	NULL
IL-2	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
Ag	NULL
,	NULL
or	NULL
Ag	NULL
plus	NULL
costimulation	NULL
,	NULL
with	NULL
only	NULL
1.3-fold	NULL
induction	NULL
over	NULL
levels	NULL
in	NULL
unstimulated	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
-	NULL
180	NULL
AP-1	NULL
site	NULL
appears	NULL
to	NULL
provide	NULL
a	NULL
positive	NULL
signal	NULL
,	NULL
and	NULL
is	NULL
not	NULL
responsible	NULL
for	NULL
repressing	NULL
IL-2	NULL
transcription	NULL
in	NULL
CDS*	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
-150	NULL
CD28RE/AP-1	NULL
site	NULL
is	NULL
selectively	NULL
not	NULL
transactivated	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
in	NULL
IL-2~	NULL
CD8	NULL
T	NULL
cells	NULL
The	NULL
three	NULL
enhancer	NULL
binding	NULL
sites	NULL
for	NULL
NFAT/AP-1	NULL
,	NULL
OCT/AP-1	NULL
,	NULL
and	NULL
CD28RE/AP-1	NULL
have	NULL
been	NULL
identified	NULL
as	NULL
critical	NULL
domains	NULL
controlling	NULL
IL-2	NULL
transcription	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
transactivation	NULL
of	NULL
these	NULL
elements	NULL
,	NULL
reporter	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
L3	NULL
,	NULL
DB45	NULL
,	NULL
and	NULL
2C	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
NFAT/AP-1	NULL
binding	NULL
site	NULL
was	NULL
observed	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
Ag	NULL
stimulation	NULL
,	NULL
and	NULL
Ag	NULL
plus	NULL
costimulation	NULL
in	NULL
all	NULL
three	NULL
clones	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
multiple	NULL
subclones	NULL
for	NULL
each	NULL
transfectant	NULL
confirmed	NULL
transactivation	NULL
in	NULL
response	NULL
to	NULL
all	NULL
stimulation	NULL
conditions	NULL
.	NULL

The	NULL
OCT/AP-1-LacZ	NULL
reporter	NULL
construct	NULL
demonstrated	NULL
inducible	NULL
-gal	NULL
activity	NULL
in	NULL
all	NULL
three	NULL
clones	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
Ag	NULL
,	NULL
or	NULL
Ag	NULL
plus	NULL
costimulation	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
,	NULL
which	NULL
was	NULL
confirmed	NULL
for	NULL
L3	NULL
by	NULL
analysis	NULL
of	NULL
multiple	NULL
subclones	NULL
.	NULL

Although	NULL
this	NULL
binding	NULL
site	NULL
did	NULL
not	NULL
induce	NULL
high	NULL
levels	NULL
of	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
any	NULL
of	NULL
the	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
,	NULL
no	NULL
significant	NULL
differences	NULL
were	NULL
evident	NULL
between	NULL
the	NULL
IL-2	NULL
*	NULL
clone	NULL
and	NULL
IL-2~	NULL
clones	NULL
.	NULL

Thus	NULL
,	NULL
neither	NULL
the	NULL
NFAT/AP-1	NULL
nor	NULL
OCT/AP-1	NULL
binding	NULL
site	NULL
appear	NULL
to	NULL
be	NULL
targets	NULL
for	NULL
differential	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
IL-2~	NULL
clones	NULL
L3	NULL
and	NULL
DB45	NULL
,	NULL
despite	NULL
being	NULL
CD28	NULL
*	NULL
,	NULL
induced	NULL
the	NULL
CD28RE/AP-1-LacZ	NULL
reporter	NULL
construct	NULL
only	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
and	NULL
failed	NULL
to	NULL
induce	NULL
B-gal	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
,	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
costimulation	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

This	NULL
was	NULL
again	NULL
confirmed	NULL
by	NULL
analysis	NULL
of	NULL
a	NULL
panel	NULL
of	NULL
L3	NULL
6533	NULL
A.	NULL
PROXIMAL	NULL
IL-2	NULL
PROMOTER	NULL
NFAT/AP-1	NULL
OCT	NULL
NF-KB	NULL
AP-	NULL
CD28RE/APA1	NULL
NFAT	NULL
APA/OCT	NULL
LacZ	NULL
CTACATCCATTCTTGCAGTCTTGG	NULL
-180	NULL
AP-1	NULL
Null	NULL
Mutation	NULL
GAAATTCCAATGACTCAGTCTTTGGGGGTTTAAA	NULL
CD28RE/AP-1	NULL
Consensqs	NULL
Addition	NULL
GAAATTCCAATGACTCATCAGAAGAG	NULL
-150	NULL
AP-1	NULL
Consensus	NULL
Mutation	NULL
B.	NULL
MULTIMERIZED	NULL
BINDING	NULL
SITES	NULL
NFAT/AP-1	NULL
CD28RE/AP-1	NULL
Min	NULL
IL-2	NULL
-72	NULL
Promoter	NULL
+47	NULL
AP-1	NULL
Consensus	NULL
FIGURE	NULL
3	NULL
.	NULL

Schematics	NULL
of	NULL
LacZH	NULL
reporter	NULL
gene	NULL
constructs	NULL
.	NULL

A	NULL
,	NULL
IL-2-LacZH	NULL
contains	NULL
the	NULL
proximal	NULL
human	NULL
IL-2	NULL
promoter	NULL
(	NULL
-326	NULL
to	NULL
+47	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
lacZ	NULL
gene	NULL
.	NULL

The	NULL
-180	NULL
AP-1	NULL
null	NULL
mutation	NULL
,	NULL
-150	NULL
AP-1	NULL
consensus	NULL
mutation	NULL
,	NULL
and	NULL
insertion	NULL
of	NULL
the	NULL
CD28RE/AP-1	NULL
consensus	NULL
site	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

B	NULL
,	NULL
All	NULL
multimerized	NULL
elements	NULL
were	NULL
linked	NULL
to	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
containing	NULL
the	NULL
TATA	NULL
box	NULL
and	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
-72	NULL
to	NULL
+47	NULL
)	NULL
preceding	NULL
the	NULL
lacZ	NULL
gene	NULL
.	NULL

and	NULL
DB45	NULL
subclones	NULL
.	NULL

However	NULL
,	NULL
IL-2	NULL
*	NULL
2C	NULL
transfectants	NULL
exhibited	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
all	NULL
three	NULL
stimuli	NULL
,	NULL
with	NULL
the	NULL
strongest	NULL
response	NULL
induced	NULL
by	NULL
Ag	NULL
plus	NULL
costimulation	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
this	NULL
enhancer	NULL
element	NULL
in	NULL
all	NULL
three	NULL
clones	NULL
mirrored	NULL
those	NULL
observed	NULL
for	NULL
the	NULL
intact	NULL
proximal	NULL
IL-2	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
and	NULL
Ag	NULL
recognition	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
CD28RE/AP-1	NULL
element	NULL
may	NULL
be	NULL
subject	NULL
to	NULL
differential	NULL
regulation	NULL
in	NULL
subpopulations	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

IL-2~	NULL
CD8¢	NULL
T	NULL
cells	NULL
express	NULL
functional	NULL
AP-1	NULL
complexes	NULL
Although	NULL
all	NULL
of	NULL
the	NULL
analyzed	NULL
reporter	NULL
constructs	NULL
of	NULL
multimerized	NULL
binding	NULL
elements	NULL
represent	NULL
composite	NULL
sites	NULL
containing	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
each	NULL
composite	NULL
site	NULL
may	NULL
bind	NULL
different	NULL
combinations	NULL
of	NULL
Jun	NULL
and/or	NULL
Fos	NULL
family	NULL
members	NULL
.	NULL

Therefore	NULL
,	NULL
to	NULL
determine	NULL
whether	NULL
a	NULL
general	NULL
defect	NULL
in	NULL
AP-1	NULL
or	NULL
a	NULL
defect	NULL
specific	NULL
to	NULL
the	NULL
nonconsensus	NULL
-150	NULL
AP-1	NULL
site	NULL
exists	NULL
in	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
transactivation	NULL
of	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
was	NULL
examined	NULL
.	NULL

The	NULL
consensus	NULL
AP-1	NULL
site	NULL
differs	NULL
from	NULL
the	NULL
CD28RE/AP-1	NULL
site	NULL
in	NULL
two	NULL
significant	NULL
ways	NULL
:	NULL
it	NULL
does	NULL
not	NULL
contain	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
CD28	NULL
response	NULL
complex	NULL
,	NULL
and	NULL
it	NULL
exhibits	NULL
higher	NULL
affinity	NULL
for	NULL
the	NULL
Jun/Fos	NULL
heterodimer	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
multimerized	NULL
consensus	NULL
AP-1-LacZ	NULL
reporter	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
was	NULL
induced	NULL
following	NULL
activation	NULL
of	NULL
L3	NULL
,	NULL
DB45	NULL
,	NULL
and	NULL
2C	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
Ag	NULL
,	NULL
and	NULL
Ag	NULL
plus	NULL
costimulation	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
)	NULL
.	NULL

These	NULL
results	NULL
,	NULL
confirmed	NULL
by	NULL
analysis	NULL
of	NULL
a	NULL
panel	NULL
of	NULL
subclones	NULL
for	NULL
each	NULL
transfectant	NULL
,	NULL
suggest	NULL
that	NULL
functional	NULL
AP-1	NULL
complexes	NULL
are	NULL
being	NULL
induced	NULL
in	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
recognition	NULL
.	NULL

Mutation	NULL
of	NULL
-150	NULL
AP-1	NULL
site	NULL
to	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
restores	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
The	NULL
failure	NULL
of	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
transactivate	NULL
the	NULL
CD28RE/	NULL
AP-1	NULL
site	NULL
could	NULL
reflect	NULL
either	NULL
a	NULL
defect	NULL
in	NULL
the	NULL
CD28	NULL
response	NULL
complex	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
CD28RE	NULL
and/or	NULL
a	NULL
defect	NULL
in	NULL
specific	NULL
AP-1	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6534	NULL
TRANSCRIPTIONAL	NULL
BLOCK	NULL
AT	NULL
-150	NULL
AP-1	NULL
SITE	NULL
IN	NULL
CD	NULL
#	NULL
8	NULL
#	NULL
*	NULL
T	NULL
CELLS	NULL
A	NULL
B	NULL
IL-2	NULL
~180	NULL
AP-1	NULL
PROMOTER	NULL
MUTATION	NULL
8	NULL
L3	NULL
6	NULL
*	NULL
?	NULL

g	NULL
4	NULL
&	NULL
2	NULL
o	NULL
0	NULL
pB4s5	NULL
°	NULL
“	NULL
Po	NULL
6	NULL
%	NULL
4	NULL
&	NULL
|	NULL
o	NULL
2	NULL
0	NULL
40	NULL
2C	NULL
l	NULL
|	NULL
4	NULL
Q	NULL
unstim	NULL
MMp+	NULL
E	NULL
pais	NULL
&	NULL
reis	NULL
s7-1+2	NULL
FIGURE	NULL
4	NULL
.	NULL

Disruption	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
-180	NULL
AP-1	NULL
site	NULL
mutation	NULL
.	NULL

L3	NULL
,	NULL
DB45	NULL
,	NULL
and	NULL
2C	NULL
transfectants	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
h	NULL
with	NULL
medium	NULL
(	NULL
unstimulated	NULL
)	NULL
,	NULL
Ag	NULL
,	NULL
(	NULL
P815	NULL
)	NULL
,	NULL
Ag	NULL
plus	NULL
costimulation	NULL
(	NULL
P815/B7-1	NULL
+	NULL
2	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
.	NULL

B-gal	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
counts	NULL
per	NULL
second	NULL
(	NULL
CPS	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Bar	NULL
graphs	NULL
represent	NULL
the	NULL
mean	NULL
from	NULL
three	NULL
replicates	NULL
+	NULL
SEM	NULL
.	NULL

A	NULL
,	NULL
IL-2-LacZH	NULL
transfectants	NULL
.	NULL

B	NULL
,	NULL
IL-2-LacZH	NULL
with	NULL
-180	NULL
AP-1	NULL
``	NULL
null	NULL
``	NULL
mutation	NULL
.	NULL

For	NULL
both	NULL
A	NULL
and	NULL
B	NULL
,	NULL
transfectants	NULL
of	NULL
L3	NULL
and	NULL
DB45	NULL
are	NULL
shown	NULL
that	NULL
represent	NULL
the	NULL
mean	NULL
induction	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
six	NULL
subclones	NULL
for	NULL
each	NULL
transfectant	NULL
.	NULL

Activity	NULL
of	NULL
2C	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
transfected	NULL
clonal	NULL
population	NULL
.	NULL

complexes	NULL
required	NULL
to	NULL
transactivate	NULL
the	NULL
AP-1	NULL
component	NULL
of	NULL
the	NULL
composite	NULL
site	NULL
,	NULL
because	NULL
both	NULL
sites	NULL
must	NULL
be	NULL
occupied	NULL
for	NULL
enhancer	NULL
activity	NULL
(	NULL
25	NULL
)	NULL
.	NULL

To	NULL
directly	NULL
assess	NULL
the	NULL
AP-1	NULL
site	NULL
,	NULL
we	NULL
left	NULL
the	NULL
CD28RE	NULL
intact	NULL
,	NULL
but	NULL
replaced	NULL
the	NULL
native	NULL
-150	NULL
AGAGTCA	NULL
AP-1	NULL
site	NULL
with	NULL
the	NULL
consensus	NULL
AP-1	NULL
motif	NULL
TGACTCA	NULL
,	NULL
and	NULL
transfected	NULL
this	NULL
modified	NULL
IL-2	NULL
promoter-LacZ	NULL
reporter	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
into	NULL
L3	NULL
,	NULL
DB45	NULL
,	NULL
and	NULL
2C	NULL
.	NULL

In	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
all	NULL
three	NULL
clones	NULL
transactivated	NULL
the	NULL
mutated	NULL
IL-2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

More-over	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
native	NULL
IL-2	NULL
promoter	NULL
,	NULL
detectable	NULL
B-gal	NULL
activity	NULL
from	NULL
the	NULL
modified	NULL
-150	NULL
AP-1	NULL
consensus	NULL
IL-2	NULL
promoter	NULL
was	NULL
induced	NULL
by	NULL
Ag	NULL
in	NULL
L3	NULL
and	NULL
DB45	NULL
,	NULL
and	NULL
was	NULL
further	NULL
increased	NULL
by	NULL
costimulation	NULL
.	NULL

Clone	NULL
2C	NULL
exhibited	NULL
high	NULL
levels	NULL
of	NULL
B-gal	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
and	NULL
Ag	NULL
plus	NULL
costimulation	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
activation	NULL
was	NULL
confirmed	NULL
by	NULL
subclone	NULL
analyses	NULL
with	NULL
L3	NULL
and	NULL
2C	NULL
.	NULL

Thus	NULL
,	NULL
conversion	NULL
of	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
to	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
appears	NULL
sufficient	NULL
to	NULL
at	NULL
least	NULL
partially	NULL
restore	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
in	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
containing	NULL
the	NULL
-150	NULL
AP-1	NULL
consensus	NULL
mutation	NULL
in	NULL
IL-2~	NULL
CD8*	NULL
clones	NULL
could	NULL
have	NULL
resulted	NULL
from	NULL
replacement	NULL
of	NULL
an	NULL
AP-1	NULL
site	NULL
requiring	NULL
specific	NULL
AP-1	NULL
family	NULL
members	NULL
that	NULL
are	NULL
not	NULL
present	NULL
with	NULL
a	NULL
binding	NULL
site	NULL
capable	NULL
of	NULL
being	NULL
transactivated	NULL
by	NULL
alternate	NULL
AP-1	NULL
complexes	NULL
,	NULL
or	NULL
from	NULL
disruption	NULL
of	NULL
a	NULL
site	NULL
that	NULL
previously	NULL
bound	NULL
a	NULL
negative	NULL
regulator	NULL
.	NULL

To	NULL
distinguish	NULL
between	NULL
these	NULL
two	NULL
possibilities	NULL
,	NULL
the	NULL
native	NULL
IL-2	NULL
promoter	NULL
was	NULL
altered	NULL
by	NULL
insertion	NULL
of	NULL
a	NULL
modified	NULL
CD28RE/AP-1	NULL
element	NULL
containing	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
between	NULL
the	NULL
-180	NULL
and	NULL
-150	NULL
enhancer	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
adds	NULL
a	NULL
functional	NULL
CD28RE/AP-1	NULL
site	NULL
to	NULL
the	NULL
promoter	NULL
while	NULL
leaving	NULL
the	NULL
native	NULL
CD28RE/AP-1	NULL
site	NULL
intact	NULL
and	NULL
potentially	NULL
capable	NULL
of	NULL
binding	NULL
a	NULL
negative	NULL
regulator	NULL
.	NULL

This	NULL
modified	NULL
IL-2	NULL
promoter	NULL
was	NULL
responsive	NULL
to	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
to	NULL
Ag	NULL
,	NULL
A	NULL
B	NULL
C	NULL
OCT/AP-1	NULL
_	NULL
CD28RE/AP-1	NULL
mt	NULL
-3	NULL
CPS	NULL
x10	NULL
DB45	NULL
-3	NULL
CPS	NULL
x10	NULL
Io	NULL
O	NULL
-3	NULL
CPS	NULL
x10	NULL
(	NULL
Q	NULL
]	NULL
unstim	NULL
Mre	NULL
E	NULL
psis	NULL
pais	NULL
s7-1+2	NULL
FIGURE	NULL
5	NULL
.	NULL

Selective	NULL
transactivation	NULL
of	NULL
composite	NULL
AP-1	NULL
sites	NULL
in	NULL
IL-2	NULL
promoter	NULL
.	NULL

L3	NULL
,	NULL
DB45	NULL
,	NULL
and	NULL
2C	NULL
transfectants	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
h	NULL
with	NULL
medium	NULL
(	NULL
unstimulated	NULL
)	NULL
,	NULL
Ag	NULL
,	NULL
(	NULL
P815	NULL
)	NULL
,	NULL
Ag	NULL
plus	NULL
costimulation	NULL
(	NULL
P815/B7-1	NULL
+	NULL
2	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
P+1	NULL
.	NULL

B-gal	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
CPS	NULL
.	NULL

Bar	NULL
graphs	NULL
represent	NULL
the	NULL
mean	NULL
from	NULL
three	NULL
replicates	NULL
+	NULL
SEM	NULL
.	NULL

A	NULL
,	NULL
NFAT/AP-1-LacZH	NULL
:	NULL
L3	NULL
,	NULL
DB45	NULL
,	NULL
and	NULL
2C	NULL
transfectants	NULL
shown	NULL
represent	NULL
the	NULL
mean	NULL
activity	NULL
detected	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
six	NULL
subclones	NULL
for	NULL
each	NULL
transfectant	NULL
.	NULL

B	NULL
,	NULL
OCT/AP-1-LacZH	NULL
:	NULL
the	NULL
representative	NULL
mean	NULL
transfectant	NULL
from	NULL
a	NULL
panel	NULL
of	NULL
six	NULL
subclones	NULL
is	NULL
shown	NULL
for	NULL
L3	NULL
;	NULL
DB45	NULL
and	NULL
2C	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
transfected	NULL
clonal	NULL
populations	NULL
.	NULL

C	NULL
,	NULL
CD28RE/AP-1-LacZH	NULL
:	NULL
representative	NULL
mean	NULL
transfectants	NULL
from	NULL
panels	NULL
of	NULL
six	NULL
subclones	NULL
each	NULL
are	NULL
shown	NULL
for	NULL
L3	NULL
and	NULL
DB45	NULL
;	NULL
activity	NULL
of	NULL
2C	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
transfected	NULL
clonal	NULL
population	NULL
.	NULL

and	NULL
to	NULL
Ag	NULL
plus	NULL
costimulation	NULL
in	NULL
all	NULL
three	NULL
CD8	NULL
*	NULL
clones	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
all	NULL
stimuli	NULL
was	NULL
consistent	NULL
among	NULL
all	NULL
L3	NULL
and	NULL
2C	NULL
subclones	NULL
.	NULL

However	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
higher	NULL
levels	NULL
of	NULL
reporter	NULL
gene	NULL
activity	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
2C	NULL
transfectant	NULL
than	NULL
in	NULL
L3	NULL
and	NULL
DB45	NULL
.	NULL

This	NULL
increase	NULL
might	NULL
reflect	NULL
a	NULL
greater	NULL
trans-gene	NULL
copy	NULL
number	NULL
in	NULL
the	NULL
2C	NULL
transfectant	NULL
,	NULL
but	NULL
we	NULL
can	NULL
not	NULL
completely	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
of	NULL
partial	NULL
repressor	NULL
activity	NULL
at	NULL
this	NULL
site	NULL
in	NULL
L3	NULL
and	NULL
DB45	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
functional	NULL
CD28RE/	NULL
AP-1	NULL
site	NULL
could	NULL
conceivably	NULL
override	NULL
or	NULL
displace	NULL
a	NULL
repressor	NULL
binding	NULL
at	NULL
the	NULL
-ISOAP-1	NULL
site	NULL
in	NULL
the	NULL
native	NULL
promoter	NULL
,	NULL
or	NULL
alternatively	NULL
restore	NULL
transactivation	NULL
by	NULL
providing	NULL
a	NULL
composite	NULL
site	NULL
that	NULL
can	NULL
bind	NULL
AP-1	NULL
complexes	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
recognition	NULL
.	NULL

Discussion	NULL
Recent	NULL
evidence	NULL
demonstrating	NULL
that	NULL
a	NULL
CREB/cAMP	NULL
response	NULL
element	NULL
modulator	NULL
complex	NULL
binds	NULL
to	NULL
the	NULL
-180	NULL
AP-1	NULL
site	NULL
in	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
negatively	NULL
regulates	NULL
IL-2	NULL
transcription	NULL
suggested	NULL
that	NULL
a	NULL
similar	NULL
or	NULL
related	NULL
complex	NULL
may	NULL
restrict	NULL
IL-2	NULL
expression	NULL
in	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
mutations	NULL
we	NULL
made	NULL
in	NULL
the	NULL
-180	NULL
AP-1	NULL
site	NULL
,	NULL
known	NULL
to	NULL
disrupt	NULL
that	NULL
site	NULL
and	NULL
restore	NULL
promoter	NULL
activity	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
21	NULL
)	NULL
,	NULL
suggested	NULL
an	NULL
alternative	NULL
mechanism	NULL
must	NULL
be	NULL
operative	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
inhibitory	NULL
mechanism	NULL
operating	NULL
at	NULL
the	NULL
-180	NULL
AP-1	NULL
site	NULL
,	NULL
a	NULL
defect	NULL
at	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
anergy	NULL
induction	NULL
(	NULL
19-21	NULL
)	NULL
,	NULL
and	NULL
we	NULL
have	NULL
identified	NULL
that	NULL
this	NULL
site	NULL
is	NULL
also	NULL
targeted	NULL
in	NULL
the	NULL
restriction	NULL
of	NULL
IL-2	NULL
production	NULL
by	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

One	NULL
possibility	NULL
for	NULL
the	NULL
observed	NULL
failure	NULL
of	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
transactivate	NULL
the	NULL
nonconsensus	NULL
-150	NULL
AP-1	NULL
site	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
is	NULL
that	NULL
the	NULL
obligatory	NULL
transcription	NULL
factors	NULL
were	NULL
not	NULL
induced	NULL
or	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
B	NULL
C	NULL
AP	NULL
150	NULL
AP	NULL
CD28RE/AP-1	NULL
MULTIMER	NULL
MUTATION	NULL
ADDITION	NULL
L3	NULL
(	NULL
7°	NULL
%	NULL
Ed	NULL
D.	NULL
o	NULL
DB45	NULL
N	NULL
0	NULL
%	NULL
d	NULL
D.	NULL
o	NULL
2C	NULL
$	NULL
0	NULL
i	NULL
®	NULL
O.	NULL
o	NULL
{	NULL
Q	NULL
unstim	NULL
Mire	NULL
E	NULL
psis	NULL
pais	NULL
ez-1+2	NULL
FIGURE	NULL
6	NULL
.	NULL

Restoration	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
consensus	NULL
AP-1	NULL
site	NULL
mutations	NULL
.	NULL

L3	NULL
,	NULL
DB45	NULL
,	NULL
and	NULL
2C	NULL
transfectants	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
h	NULL
with	NULL
medium	NULL
(	NULL
unstimulated	NULL
)	NULL
,	NULL
Ag	NULL
,	NULL
(	NULL
P815	NULL
)	NULL
,	NULL
Ag	NULL
plus	NULL
costimulation	NULL
(	NULL
P815/B7-1	NULL
+	NULL
2	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
P+1	NULL
.	NULL

B-gal	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
CPS	NULL
.	NULL

Bar	NULL
graphs	NULL
represent	NULL
the	NULL
mean	NULL
from	NULL
three	NULL
replicates	NULL
+	NULL
SEM	NULL
.	NULL

A	NULL
,	NULL
Multimerized	NULL
AP-1	NULL
consensus-LacZH	NULL
:	NULL
L3	NULL
,	NULL
DB45	NULL
and	NULL
2C	NULL
transfectants	NULL
representing	NULL
the	NULL
average	NULL
level	NULL
of	NULL
induction	NULL
measured	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
six	NULL
subclones	NULL
each	NULL
are	NULL
shown	NULL
.	NULL

B	NULL
,	NULL
IL-2-LacZH	NULL
with	NULL
-150	NULL
AP-1	NULL
consensus	NULL
mutation	NULL
.	NULL

C	NULL
,	NULL
IL-2-LacZH	NULL
with	NULL
CD28RE/AP-1	NULL
consensus	NULL
insertion	NULL
.	NULL

For	NULL
both	NULL
B	NULL
and	NULL
C	NULL
,	NULL
mean	NULL
transfectants	NULL
from	NULL
panels	NULL
of	NULL
six	NULL
subclones	NULL
each	NULL
are	NULL
represented	NULL
for	NULL
L3	NULL
and	NULL
2C	NULL
,	NULL
and	NULL
activity	NULL
of	NULL
DB45	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
transfected	NULL
clonal	NULL
population	NULL
.	NULL

activated	NULL
.	NULL

Members	NULL
of	NULL
the	NULL
activating	NULL
transcription	NULL
factor-1/CREB	NULL
family	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
transactivate	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
(	NULL
37	NULL
)	NULL
,	NULL
representing	NULL
one	NULL
possible	NULL
complex	NULL
that	NULL
could	NULL
act	NULL
to	NULL
differentially	NULL
regulate	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
.	NULL

A	NULL
second	NULL
possibility	NULL
is	NULL
that	NULL
the	NULL
requisite	NULL
Fos	NULL
or	NULL
Jun	NULL
family	NULL
member	NULL
(	NULL
s	NULL
)	NULL
were	NULL
not	NULL
induced	NULL
or	NULL
appropriately	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
antigenic	NULL
stimulation	NULL
.	NULL

AP-1	NULL
complexes	NULL
can	NULL
consist	NULL
of	NULL
different	NULL
dimeric	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
members	NULL
and	NULL
exhibit	NULL
variable	NULL
DNA	NULL
binding	NULL
specificity	NULL
.	NULL

Although	NULL
Jun/Jun	NULL
homodimers	NULL
can	NULL
transactivate	NULL
AP-1	NULL
sites	NULL
,	NULL
Fos/Jun	NULL
heterodimers	NULL
are	NULL
more	NULL
potent	NULL
transactivators	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
nonconsensus	NULL
-150	NULL
AP-1	NULL
site	NULL
is	NULL
a	NULL
``	NULL
low	NULL
affinity	NULL
``	NULL
site	NULL
for	NULL
the	NULL
Fos/Jun	NULL
heterodimer	NULL
(	NULL
36	NULL
)	NULL
,	NULL
and	NULL
may	NULL
require	NULL
a	NULL
specific	NULL
combination	NULL
of	NULL
Fos/Jun	NULL
family	NULL
members	NULL
for	NULL
activation	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
NFAT/AP-1	NULL
site	NULL
and	NULL
consensus	NULL
AP-1	NULL
sites	NULL
are	NULL
``	NULL
high	NULL
affinity	NULL
``	NULL
binding	NULL
sites	NULL
and	NULL
can	NULL
be	NULL
transactivated	NULL
with	NULL
both	NULL
Fos/Jun	NULL
and	NULL
Jun/Jun	NULL
dimers	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
transactivate	NULL
the	NULL
NFAT/AP-1	NULL
,	NULL
OCT/AP-1	NULL
,	NULL
and	NULL
consensus	NULL
AP-1	NULL
sites	NULL
but	NULL
not	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
could	NULL
result	NULL
from	NULL
limitation	NULL
or	NULL
inactivation	NULL
of	NULL
a	NULL
required	NULL
factor	NULL
,	NULL
such	NULL
as	NULL
one	NULL
of	NULL
the	NULL
Fos	NULL
proteins	NULL
.	NULL

Several	NULL
Fos	NULL
family	NULL
members	NULL
such	NULL
as	NULL
Fral	NULL
,	NULL
Fra2	NULL
,	NULL
and	NULL
an	NULL
alternatively	NULL
spliced	NULL
form	NULL
of	NULL
FosB	NULL
lack	NULL
transcriptional	NULL
activation	NULL
domains	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

These	NULL
transcriptionally	NULL
inactive	NULL
forms	NULL
of	NULL
Fos	NULL
might	NULL
have	NULL
preferential	NULL
affinity	NULL
for	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
while	NULL
not	NULL
efficiently	NULL
binding	NULL
and	NULL
interfering	NULL
with	NULL
transactivation	NULL
of	NULL
the	NULL
NFAT/AP-1	NULL
,	NULL
OCT/AP-1	NULL
,	NULL
or	NULL
consensus	NULL
AP-1	NULL
sites	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
antigenic	NULL
stimulation	NULL
of	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
does	NULL
not	NULL
result	NULL
in	NULL
the	NULL
induction	NULL
or	NULL
activation	NULL
of	NULL
the	NULL
specific	NULL
nuclear	NULL
proteins	NULL
required	NULL
to	NULL
transactivate	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
,	NULL
and	NULL
consequently	NULL
the	NULL
entire	NULL
IL-2	NULL
promoter	NULL
is	NULL
rendered	NULL
inactive	NULL
.	NULL

Protein-DNA	NULL
interactions	NULL
at	NULL
distal	NULL
sites	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
unstable	NULL
if	NULL
6535	NULL
even	NULL
one	NULL
transcription	NULL
factor	NULL
is	NULL
missing	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
possibility	NULL
that	NULL
a	NULL
missing	NULL
factor	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
differences	NULL
in	NULL
cytokine	NULL
secretion	NULL
patterns	NULL
in	NULL
IL-2	NULL
*	NULL
and	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
is	NULL
consistent	NULL
with	NULL
studies	NULL
using	NULL
heterokaryons	NULL
between	NULL
CD4*	NULL
and	NULL
CD8	NULL
#	NULL
*	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

In	NULL
those	NULL
studies	NULL
,	NULL
fusion	NULL
of	NULL
the	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clone	NULL
L3	NULL
with	NULL
an	NULL
CD4*	NULL
fusion	NULL
partner	NULL
did	NULL
not	NULL
repress	NULL
secretion	NULL
of	NULL
IL-2	NULL
,	NULL
suggesting	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
regulatory	NULL
factor	NULL
for	NULL
IL-2	NULL
expression	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
43	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
heterokaryon	NULL
formation	NULL
between	NULL
nonanergic	NULL
and	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
disrupted	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
in	NULL
the	NULL
fusion	NULL
partner	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
regulatory	NULL
mechanism	NULL
for	NULL
restriction	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
did	NULL
not	NULL
examine	NULL
potential	NULL
signaling	NULL
defects	NULL
in	NULL
this	NULL
study	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
suggest	NULL
that	NULL
the	NULL
failure	NULL
of	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
may	NULL
lie	NULL
in	NULL
their	NULL
failure	NULL
to	NULL
adequately	NULL
transmit	NULL
a	NULL
costimulatory	NULL
signal	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
inability	NULL
to	NULL
transactivate	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
specific	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
would	NULL
provide	NULL
insight	NULL
into	NULL
which	NULL
signaling	NULL
molecules	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
restriction	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
light	NULL
of	NULL
the	NULL
potential	NULL
role	NULL
of	NULL
activating	NULL
transcription	NULL
factor/CREB	NULL
family	NULL
members	NULL
at	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
(	NULL
37	NULL
)	NULL
,	NULL
it	NULL
might	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
examine	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
.	NULL

Other	NULL
candidates	NULL
include	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
,	NULL
Fos	NULL
regulating	NULL
kinase	NULL
(	NULL
FRK	NULL
)	NULL
,	NULL
and	NULL
Jun	NULL
amino-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
,	NULL
that	NULL
function	NULL
downstream	NULL
of	NULL
Ras	NULL
,	NULL
and	NULL
act	NULL
together	NULL
to	NULL
regulate	NULL
the	NULL
expression	NULL
and	NULL
function	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
45-47	NULL
)	NULL
.	NULL

ERK	NULL
induces	NULL
the	NULL
transcription	NULL
of	NULL
fos	NULL
mRNA	NULL
by	NULL
phosphory-lating	NULL
the	NULL
Elk-1	NULL
transcription	NULL
factor	NULL
in	NULL
the	NULL
fos	NULL
promoter	NULL
(	NULL
48	NULL
)	NULL
,	NULL
FRK	NULL
acts	NULL
to	NULL
enhance	NULL
transcriptional	NULL
activation	NULL
of	NULL
Fos	NULL
proteins	NULL
by	NULL
phosphorylation	NULL
(	NULL
46	NULL
)	NULL
,	NULL
and	NULL
JNK	NULL
phosphorylates	NULL
and	NULL
activates	NULL
Jun	NULL
proteins	NULL
(	NULL
47	NULL
)	NULL
.	NULL

In	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
Ras	NULL
activation	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
selectively	NULL
blocked	NULL
,	NULL
leading	NULL
to	NULL
reduced	NULL
activity	NULL
of	NULL
ERK	NULL
and	NULL
JNK	NULL
,	NULL
but	NULL
treatment	NULL
with	NULL
PMA	NULL
,	NULL
which	NULL
bypasses	NULL
the	NULL
TCR	NULL
to	NULL
activate	NULL
the	NULL
Ras	NULL
signaling	NULL
pathway	NULL
,	NULL
restored	NULL
activation	NULL
of	NULL
both	NULL
ERK	NULL
and	NULL
JNK	NULL
and	NULL
partially	NULL
restored	NULL
IL-2	NULL
production	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
stimulation	NULL
with	NULL
ionomycin	NULL
plus	NULL
PMA	NULL
induced	NULL
IL-2	NULL
gene	NULL
transcription	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
that	NULL
do	NULL
not	NULL
produce	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
suggests	NULL
that	NULL
the	NULL
Ras	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathway	NULL
may	NULL
not	NULL
be	NULL
efficiently	NULL
activated	NULL
by	NULL
Ag	NULL
stimulation	NULL
in	NULL
IL-2	NULL
,	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
NFAT/AP-1	NULL
,	NULL
OCT/AP-1	NULL
,	NULL
and	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
were	NULL
transactivated	NULL
in	NULL
response	NULL
to	NULL
Ag	NULL
,	NULL
this	NULL
does	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
JNK	NULL
was	NULL
inactive	NULL
in	NULL
IL-2~	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Studies	NULL
in	NULL
anergic	NULL
cells	NULL
have	NULL
shown	NULL
that	NULL
some	NULL
AP-1	NULL
sites	NULL
remain	NULL
functional	NULL
,	NULL
despite	NULL
the	NULL
apparent	NULL
block	NULL
in	NULL
JNK	NULL
activation	NULL
(	NULL
20	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
jun	NULL
proteins	NULL
that	NULL
are	NULL
not	NULL
phosphorylated	NULL
by	NULL
JNK	NULL
,	NULL
such	NULL
as	NULL
JunB	NULL
,	NULL
could	NULL
act	NULL
to	NULL
transactivate	NULL
certain	NULL
AP-1	NULL
sites	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Even	NULL
if	NULL
JNK	NULL
was	NULL
active	NULL
,	NULL
transactivation	NULL
of	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
also	NULL
requires	NULL
transcriptionally	NULL
active	NULL
fos	NULL
protein	NULL
.	NULL

The	NULL
only	NULL
mechanism	NULL
for	NULL
inducing	NULL
and	NULL
activating	NULL
Fos	NULL
proteins	NULL
is	NULL
through	NULL
ERK	NULL
and	NULL
FRK	NULL
,	NULL
which	NULL
are	NULL
both	NULL
dependent	NULL
on	NULL
Ras	NULL
activity	NULL
.	NULL

Consequently	NULL
,	NULL
a	NULL
block	NULL
in	NULL
the	NULL
Ras	NULL
pathway	NULL
could	NULL
specifically	NULL
affect	NULL
the	NULL
expression	NULL
and	NULL
activation	NULL
of	NULL
Fos	NULL
proteins	NULL
,	NULL
leading	NULL
to	NULL
impaired	NULL
transactivation	NULL
of	NULL
sites	NULL
requiring	NULL
Fos/Jun	NULL
heterodimers	NULL
and	NULL
resulting	NULL
in	NULL
the	NULL
failure	NULL
of	NULL
effector	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
cells	NULL
may	NULL
have	NULL
evolved	NULL
to	NULL
lose	NULL
the	NULL
capacity	NULL
for	NULL
IL-2	NULL
expression	NULL
to	NULL
provide	NULL
an	NULL
additional	NULL
regulatory	NULL
mechanism	NULL
for	NULL
avoiding	NULL
autoimmune	NULL
tissue	NULL
damage	NULL
caused	NULL
by	NULL
self-reactive	NULL
CTL	NULL
that	NULL
escape	NULL
thymic	NULL
deletion	NULL
.	NULL

Although	NULL
there	NULL
are	NULL
settings	NULL
in	NULL
which	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
can	NULL
respond	NULL
independently	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
such	NULL
as	NULL
to	NULL
clear	NULL
certain	NULL
acute	NULL
viral	NULL
infections	NULL
,	NULL
immune	NULL
responses	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD4	NULL
help	NULL
generally	NULL
are	NULL
limited	NULL
in	NULL
magnitude	NULL
and	NULL
do	NULL
not	NULL
persist	NULL
long-term	NULL
(	NULL
2-6	NULL
)	NULL
.	NULL

Mechanistically	NULL
,	NULL
the	NULL
division	NULL
of	NULL
roles	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
compartment	NULL
could	NULL
be	NULL
governed	NULL
by	NULL
the	NULL
different	NULL
types	NULL
of	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6536	NULL
TRANSCRIPTIONAL	NULL
BLOCK	NULL
AT	NULL
-150	NULL
AP-1	NULL
SITE	NULL
IN	NULL
CD	NULL
#	NULL
8	NULL
#	NULL
*	NULL
T	NULL
CELLS	NULL
APC	NULL
recognized	NULL
by	NULL
CD4*	NULL
and	NULL
CD8	NULL
#	NULL
*	NULL
T	NULL
cell	NULL
subsets	NULL
.	NULL

CD4*	NULL
T	NULL
lymphocytes	NULL
recognize	NULL
cells	NULL
bearing	NULL
Ag	NULL
in	NULL
the	NULL
context	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
,	NULL
and	NULL
these	NULL
``	NULL
professional	NULL
``	NULL
APC	NULL
usually	NULL
express	NULL
B7	NULL
molecules	NULL
.	NULL

Such	NULL
APC	NULL
are	NULL
capable	NULL
of	NULL
delivering	NULL
both	NULL
a	NULL
signal	NULL
through	NULL
the	NULL
TCR	NULL
and	NULL
a	NULL
costimulatory	NULL
signal	NULL
through	NULL
CD28	NULL
,	NULL
resulting	NULL
in	NULL
IL-2	NULL
production	NULL
by	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
lymphocytes	NULL
recognize	NULL
targets	NULL
expressing	NULL
Ag	NULL
in	NULL
the	NULL
context	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
,	NULL
and	NULL
most	NULL
of	NULL
these	NULL
cells	NULL
lack	NULL
the	NULL
costimulatory	NULL
molecules	NULL
B7-1	NULL
and	NULL
B7-2	NULL
.	NULL

After	NULL
encounter	NULL
with	NULL
Ag	NULL
on	NULL
class	NULL
I	NULL
targets	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
costimulation	NULL
,	NULL
the	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
may	NULL
become	NULL
``	NULL
anergized	NULL
``	NULL
with	NULL
respect	NULL
to	NULL
IL-2	NULL
production	NULL
while	NULL
retaining	NULL
effector	NULL
function	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
molecular	NULL
mechanism	NULL
for	NULL
inducing	NULL
and	NULL
maintaining	NULL
this	NULL
state	NULL
of	NULL
split	NULL
anergy	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
appears	NULL
to	NULL
share	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
of	NULL
the	NULL
features	NULL
that	NULL
have	NULL
been	NULL
described	NULL
in	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
greater	NULL
understanding	NULL
of	NULL
the	NULL
molecular	NULL
events	NULL
leading	NULL
to	NULL
the	NULL
anergic	NULL
state	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
could	NULL
have	NULL
implications	NULL
for	NULL
therapeutic	NULL
intervention	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
clinical	NULL
settings	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
Gerald	NULL
Crabtree	NULL
and	NULL
Dr.	NULL
Steven	NULL
Fiering	NULL
for	NULL
providing	NULL
the	NULL
LacZH	NULL
constructs	NULL
.	NULL

We	NULL
are	NULL
also	NULL
grateful	NULL
to	NULL
Kent	NULL
Slaven	NULL
,	NULL
Wendy	NULL
Walker	NULL
,	NULL
and	NULL
Katie	NULL
Weber	NULL
for	NULL
maintaining	NULL
our	NULL
mouse	NULL
colonies	NULL
,	NULL
and	NULL
we	NULL
are	NULL
indebted	NULL
to	NULL
Eric	NULL
Baker	NULL
for	NULL
his	NULL
assistance	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Miller	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

1983	NULL
.	NULL

IL-2	NULL
production	NULL
by	NULL
mitogen-stimulated	NULL
T	NULL
cell	NULL
subsets	NULL
:	NULL
helper	NULL
precursors	NULL
are	NULL
predominantly	NULL
Lyt-2	NULL
_.	NULL
J.	NULL
Immunol	NULL
.	NULL

31:2864	NULL
.	NULL

2	NULL
.	NULL

Matloubian	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
J.	NULL
Concepcion	NULL
,	NULL
and	NULL
R.	NULL
Ahmed	NULL
.	NULL

1994	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
are	NULL
required	NULL
to	NULL
sustain	NULL
CD8	NULL
*	NULL
cytotoxic	NULL
T-cell	NULL
responses	NULL
during	NULL
chronic	NULL
viral	NULL
infection	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:8056	NULL
.	NULL

3	NULL
.	NULL

Cardin	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
J.	NULL
W.	NULL
Brooks	NULL
,	NULL
S.	NULL
R.	NULL
Sarawar	NULL
,	NULL
and	NULL
P.	NULL
C.	NULL
Doherty	NULL
.	NULL

1996	NULL
.	NULL

Progressive	NULL
loss	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cell-mediated	NULL
control	NULL
of	NULL
a	NULL
y-herpesvirus	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:863	NULL
.	NULL

4	NULL
.	NULL

Rahemtulla	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
P.	NULL
Fung-Leung	NULL
,	NULL
M.	NULL
W.	NULL
Schilbham	NULL
,	NULL
T.	NULL
M.	NULL
Kundig	NULL
,	NULL
S.	NULL
R.	NULL
Sambhara	NULL
,	NULL
A.	NULL
Narendran	NULL
,	NULL
A.	NULL
Arabian	NULL
,	NULL
A.	NULL
Wakeham	NULL
,	NULL
C.	NULL
J.	NULL
Paige	NULL
,	NULL
R.	NULL
M.	NULL
Zinkernagel	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
.	NULL

Normal	NULL
development	NULL
and	NULL
function	NULL
of	NULL
CD8	NULL
*	NULL
cells	NULL
but	NULL
markedly	NULL
decreased	NULL
helper	NULL
cell	NULL
activity	NULL
in	NULL
mice	NULL
lacking	NULL
CD4	NULL
.	NULL

Nature	NULL
353:180	NULL
.	NULL

5	NULL
.	NULL

Battegay	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Moskophidis	NULL
,	NULL
A.	NULL
Rahemtulla	NULL
,	NULL
H.	NULL
Hengartner	NULL
,	NULL
T.	NULL
W.	NULL
Mak	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Zinkernagel	NULL
.	NULL

1994	NULL
.	NULL

Enhanced	NULL
establishment	NULL
of	NULL
a	NULL
virus	NULL
carrier	NULL
state	NULL
in	NULL
adult	NULL
CD4*	NULL
T-cell-deficient	NULL
mice	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:4700	NULL
.	NULL

6.	NULL
von	NULL
Herrath	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
M.	NULL
Yokoyama	NULL
,	NULL
J.	NULL
Dockter	NULL
,	NULL
M.	NULL
B.	NULL
Oldstone	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Whitton	NULL
.	NULL

1996	NULL
.	NULL

CD4-deficient	NULL
mice	NULL
have	NULL
reduced	NULL
levels	NULL
of	NULL
memory	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
after	NULL
immunization	NULL
and	NULL
show	NULL
diminished	NULL
resistance	NULL
to	NULL
subsequent	NULL
virus	NULL
challenge	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:1072	NULL
.	NULL

7	NULL
.	NULL

Ridge	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
F.	NULL
DiRosa	NULL
,	NULL
and	NULL
P.	NULL
Matzinger	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
conditioned	NULL
dendritic	NULL
cell	NULL
can	NULL
be	NULL
a	NULL
temporal	NULL
bridge	NULL
between	NULL
a	NULL
CD4*	NULL
T-helper	NULL
and	NULL
a	NULL
T-killer	NULL
cell	NULL
.	NULL

Nature	NULL
393	NULL
:	NULL
474	NULL
.	NULL

8	NULL
.	NULL

Bennett	NULL
,	NULL
S.	NULL
R.	NULL
M.	NULL
,	NULL
F.	NULL
R.	NULL
Carbone	NULL
,	NULL
F.	NULL
Karamalis	NULL
,	NULL
R.	NULL
A.	NULL
Flavell	NULL
,	NULL
J.	NULL
F.	NULL
A.	NULL
P.	NULL
Miller	NULL
,	NULL
and	NULL
W.	NULL
R.	NULL
Heath	NULL
.	NULL

1998	NULL
.	NULL

Help	NULL
for	NULL
cytotoxic	NULL
T-cell	NULL
responses	NULL
is	NULL
mediated	NULL
by	NULL
CD40	NULL
signaling	NULL
.	NULL

Nature	NULL
393:478	NULL
.	NULL

9	NULL
.	NULL

Schoenberger	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
Toes	NULL
,	NULL
E.	NULL
I.	NULL
H.	NULL
van	NULL
der	NULL
Voort	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1998	NULL
.	NULL

T	NULL
cell	NULL
help	NULL
for	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
is	NULL
mediated	NULL
by	NULL
CD40-CD40L	NULL
interactions	NULL
.	NULL

Nature	NULL
393:480	NULL
.	NULL

10	NULL
.	NULL

Lu	NULL
,	NULL
Z.	NULL
,	NULL
L.	NULL
Yuan	NULL
,	NULL
X.	NULL
Zhou	NULL
,	NULL
E.	NULL
Sotomayor	NULL
,	NULL
H.	NULL
I.	NULL
Levitsky	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Pardoll	NULL
.	NULL

2000	NULL
.	NULL

CD40-independent	NULL
pathways	NULL
of	NULL
T	NULL
cell	NULL
help	NULL
for	NULL
priming	NULL
of	NULL
CD8*	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

191:541	NULL
.	NULL

11	NULL
.	NULL

Often	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
N.	NULL
Germain	NULL
.	NULL

1991	NULL
.	NULL

Split	NULL
anergy	NULL
in	NULL
a	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
:	NULL
receptor	NULL
dependent	NULL
cytolysis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
interleukin-2	NULL
production	NULL
.	NULL

Science	NULL
251:1228	NULL
.	NULL

12	NULL
.	NULL

Chen	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Ashe	NULL
,	NULL
W.	NULL
A.	NULL
Brady	NULL
,	NULL
I.	NULL
Hellstrom	NULL
,	NULL
K.	NULL
E.	NULL
Hellstrom	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
P.	NULL
McGowan	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Linsley	NULL
.	NULL

1992	NULL
.	NULL

Costimulation	NULL
of	NULL
antitumor	NULL
immunity	NULL
by	NULL
the	NULL
B7	NULL
counterreceptor	NULL
for	NULL
the	NULL
T	NULL
lymphocyte	NULL
molecules	NULL
CD28	NULL
and	NULL
CTLA-4	NULL
.	NULL

Cell	NULL
71:1093	NULL
.	NULL

13	NULL
.	NULL

Townsend	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1993	NULL
.	NULL

Tumor	NULL
rejection	NULL
after	NULL
direct	NULL
costimulation	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
B7-transfected	NULL
melanoma	NULL
cells	NULL
.	NULL

Science	NULL
258:368	NULL
.	NULL

14	NULL
.	NULL

Fields	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
R.	NULL
J.	NULL
Finch	NULL
,	NULL
G.	NULL
S.	NULL
Gray	NULL
,	NULL
R.	NULL
Zollner	NULL
,	NULL
J.	NULL
L.	NULL
Thomas	NULL
,	NULL
K.	NULL
Sturmhoefel	NULL
,	NULL
K.	NULL
Lee	NULL
,	NULL
S.	NULL
Wolf	NULL
,	NULL
T.	NULL
F.	NULL
Gajewski	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1998	NULL
.	NULL

B7.1	NULL
is	NULL
a	NULL
quantitatively	NULL
stronger	NULL
costimulus	NULL
than	NULL
B7.2	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
naive	NULL
CD8	NULL
*	NULL
TCR-transgenic	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:5268	NULL
.	NULL

15	NULL
.	NULL

Noble	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
A.	NULL
Macary	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Kemeny	NULL
.	NULL

1995	NULL
.	NULL

IFNy	NULL
and	NULL
IL-4	NULL
regulate	NULL
the	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
into	NULL
subpopulations	NULL
with	NULL
distinct	NULL
cytokine	NULL
profiles	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:2928	NULL
.	NULL

16	NULL
.	NULL

Li	NULL
,	NULL
W.	NULL
,	NULL
C.	NULL
D.	NULL
Whaley	NULL
,	NULL
A.	NULL
Mondino	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Mueller	NULL
.	NULL

1996	NULL
.	NULL

Blocked	NULL
signal	NULL
transduction	NULL
to	NULL
the	NULL
ERK	NULL
and	NULL
JNK	NULL
protein	NULL
kinases	NULL
in	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Science	NULL
271:1272	NULL
.	NULL

17	NULL
.	NULL

Fields	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
T.	NULL
F.	NULL
Gajewski	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1996	NULL
.	NULL

Blocked	NULL
Ras	NULL
activation	NULL
in	NULL
anergic	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Science	NULL
271:1276	NULL
.	NULL

18	NULL
.	NULL

Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
D.	NULL
M.	NULL
Pardoll	NULL
,	NULL
J.	NULL
Mizuguchi	NULL
,	NULL
T.	NULL
M.	NULL
Chused	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Schwartz	NULL
.	NULL

1987	NULL
.	NULL

Molecular	NULL
events	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
non-responsive	NULL
state	NULL
in	NULL
interleukin-2	NULL
producing	NULL
helper	NULL
T-lymphocyte	NULL
clones	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:5409	NULL
.	NULL

19	NULL
.	NULL

Mondino	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
D.	NULL
Whaley	NULL
,	NULL
D.	NULL
R.	NULL
DeSilva	NULL
,	NULL
W.	NULL
Li	NULL
,	NULL
M.	NULL
K.	NULL
Jenkins	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Mueller	NULL
.	NULL

1996	NULL
.	NULL

Defective	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
is	NULL
associated	NULL
with	NULL
impaired	NULL
expression	NULL
of	NULL
c-fos	NULL
,	NULL
FosB	NULL
,	NULL
and	NULL
JunB	NULL
in	NULL
anergic	NULL
T	NULL
helper	NULL
1	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:2048	NULL
.	NULL

20	NULL
.	NULL

Kang	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
B.	NULL
Beverly	NULL
,	NULL
A.	NULL
C.	NULL
Tran	NULL
,	NULL
K.	NULL
Brorson	NULL
,	NULL
R.	NULL
H.	NULL
Schwartz	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Lenardo	NULL
.	NULL

1992	NULL
.	NULL

Transactivation	NULL
by	NULL
AP-1	NULL
is	NULL
a	NULL
molecular	NULL
target	NULL
of	NULL
T	NULL
cell	NULL
clonal	NULL
anergy	NULL
.	NULL

Science	NULL
257:1134	NULL
.	NULL

21	NULL
.	NULL

Sakakida	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Schwartz	NULL
.	NULL

1996	NULL
.	NULL

Multifactor	NULL
cis-dominant	NULL
negative	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
in	NULL
anergized	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:2328	NULL
.	NULL

22	NULL
.	NULL

Powell	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
C.	NULL
G.	NULL
Lerner	NULL
,	NULL
G.	NULL
R.	NULL
Ewoldt	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Schwartz	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
-180	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
the	NULL
target	NULL
of	NULL
CREB/CREM	NULL
binding	NULL
in	NULL
T	NULL
cell	NULL
anergy	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:6631	NULL
.	NULL

23	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Jun	NULL
,	NULL
Fos	NULL
,	NULL
and	NULL
the	NULL
AP-1	NULL
complex	NULL
in	NULL
cell-proliferation	NULL
and	NULL
transformation	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072:129	NULL
.	NULL

24	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
Z	NULL
.	NULL

Miner	NULL
,	NULL
T.	NULL
K.	NULL
Kerppola	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
T	NULL
cell	NULL
transcription	NULL
factor	NULL
NFATp	NULL
is	NULL
a	NULL
substrate	NULL
for	NULL
calcineurin	NULL
and	NULL
interacts	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Nature	NULL
365:352	NULL
.	NULL

25	NULL
.	NULL

Shapiro	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
K.	NULL
E.	NULL
Truitt	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Imboden	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1997	NULL
.	NULL

CD28	NULL
mediates	NULL
transcriptional	NULL
upregulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
through	NULL
a	NULL
composite	NULL
element	NULL
containing	NULL
the	NULL
CD28RE	NULL
and	NULL
NFIL2B	NULL
AP-1	NULL
sites	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:4051	NULL
.	NULL

26	NULL
.	NULL

De	NULL
Grazia	NULL
,	NULL
U.	NULL
,	NULL
M.	NULL
P.	NULL
Felli	NULL
,	NULL
A.	NULL
Vacca	NULL
,	NULL
A.	NULL
R.	NULL
Farina	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
L.	NULL
Cappabianca	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
M.	NULL
Farina	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1994	NULL
.	NULL

Positive	NULL
and	NULL
negative	NULL
regulation	NULL
of	NULL
the	NULL
composite	NULL
octamer	NULL
motif	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
enhancer	NULL
by	NULL
AP-1	NULL
,	NULL
Oct-2	NULL
,	NULL
and	NULL
retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1485	NULL
.	NULL

27	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.	NULL
P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715	NULL
.	NULL

28	NULL
.	NULL

Glasebrook	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1980	NULL
.	NULL

Alloreactive	NULL
cloned	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

I.	NULL
Interactions	NULL
between	NULL
cloned	NULL
amplifier	NULL
and	NULL
cytolytic	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

151:876	NULL
.	NULL

29	NULL
.	NULL

Moldwin	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
D.	NULL
W.	NULL
Lancki	NULL
,	NULL
K.	NULL
C.	NULL
Herold	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1986	NULL
.	NULL

An	NULL
antigen	NULL
receptor-driven	NULL
,	NULL
interleukin	NULL
2-independent	NULL
pathway	NULL
for	NULL
proliferation	NULL
of	NULL
murine	NULL
cytolytic	NULL
T	NULL
lymphocyte	NULL
clones	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

163:1566	NULL
.	NULL

30	NULL
.	NULL

McKisic	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
D.	NULL
W.	NULL
Lancki	NULL
,	NULL
D.	NULL
C.	NULL
Cronin	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1993	NULL
.	NULL

Cytolytic	NULL
activity	NULL
of	NULL
murine	NULL
IL-2	NULL
producing	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cell	NULL
clones	NULL
cycles	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:4055	NULL
.	NULL

31	NULL
.	NULL

Saito	NULL
,	NULL
H.	NULL
,	NULL
D.	NULL
M.	NULL
Kranz	NULL
,	NULL
Y.	NULL
Takagaki	NULL
,	NULL
A.	NULL
C.	NULL
Hayday	NULL
,	NULL
H.	NULL
N.	NULL
Eisen	NULL
,	NULL
and	NULL
S.	NULL
Tonegawa	NULL
.	NULL

1984	NULL
.	NULL

A	NULL
third	NULL
rearranged	NULL
and	NULL
expressed	NULL
gene	NULL
in	NULL
a	NULL
clone	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
312:36	NULL
.	NULL

32	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
S.	NULL
Ullman	NULL
,	NULL
S.	NULL
Ficring	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
M.	NULL
McCutcheon	NULL
,	NULL
G.	NULL
R.	NULL
Crabiree	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
actions	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
suggest	NULL
a	NULL
novel	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:4425	NULL
.	NULL

33	NULL
.	NULL

Lee	NULL
,	NULL
W.	NULL
,	NULL
P.	NULL
Mitchell	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1987	NULL
.	NULL

Purified	NULL
transcription	NULL
factor	NULL
AP-1	NULL
interacts	NULL
with	NULL
TPA-inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Cell	NULL
6:741	NULL
.	NULL

34	NULL
.	NULL

Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
S.	NULL
D.	NULL
Hunt	NULL
,	NULL
J.	NULL
K.	NULL
Pullen	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Pearce	NULL
.	NULL

1989	NULL
.	NULL

Site-directed	NULL
mu-tagenesis	NULL
by	NULL
overlap	NULL
extension	NULL
using	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Gene	NULL
77:51	NULL
.	NULL

35	NULL
.	NULL

Bondi	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Chicregatti	NULL
,	NULL
V.	NULL
Eusebi	NULL
,	NULL
E.	NULL
Fulcheri	NULL
,	NULL
and	NULL
G.	NULL
Bussolati	NULL
.	NULL

1982	NULL
.	NULL

The	NULL
use	NULL
of	NULL
B-galactosidase	NULL
as	NULL
a	NULL
tracer	NULL
in	NULL
immunocytochemistry	NULL
.	NULL

Histochemistry	NULL
76:153	NULL
.	NULL

36	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
V.	NULL
E.	NULL
Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:1240	NULL
.	NULL

37	NULL
.	NULL

Butscher	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
C.	NULL
Powers	NULL
,	NULL
M.	NULL
Olive	NULL
,	NULL
C.	NULL
Vinson	NULL
,	NULL
and	NULL
K.	NULL
Gardner	NULL
.	NULL

1998	NULL
.	NULL

Coordinate	NULL
transactivation	NULL
of	NULL
the	NULL
interleukin-2	NULL
CD28	NULL
response	NULL
element	NULL
by	NULL
c-rel	NULL
and	NULL
ATF-1/CREB2	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:552	NULL
.	NULL

38	NULL
.	NULL

Ryseck	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
and	NULL
R.	NULL
Bravo	NULL
.	NULL

1991.	NULL
c-Jun	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
JunD	NULL
differ	NULL
in	NULL
their	NULL
binding	NULL
affinities	NULL
to	NULL
AP-1	NULL
and	NULL
CRE	NULL
consensus	NULL
sequences	NULL
:	NULL
effect	NULL
of	NULL
Fos	NULL
proteins	NULL
.	NULL

Oncogene	NULL
6:533	NULL
.	NULL

39	NULL
.	NULL

Petrak	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
A.	NULL
Memon	NULL
,	NULL
M.	NULL
J.	NULL
Birrer	NULL
,	NULL
J.	NULL
D.	NULL
Ashwell	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Zacharchuk	NULL
.	NULL

1994	NULL
.	NULL

Dominant	NULL
negative	NULL
mutant	NULL
of	NULL
c-Jun	NULL
inhibits	NULL
NF-AT	NULL
transcriptional	NULL
activity	NULL
and	NULL
prevents	NULL
IL-2	NULL
gene	NULL
transcription	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:2046	NULL
.	NULL

40	NULL
.	NULL

Suzuki	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Okuno	NULL
,	NULL
T.	NULL
Yoshida	NULL
,	NULL
T.	NULL
Endo	NULL
,	NULL
H.	NULL
Nishina	NULL
,	NULL
and	NULL
H.	NULL
Iba	NULL
.	NULL

1991	NULL
.	NULL

Difference	NULL
in	NULL
transcriptional	NULL
regulatory	NULL
function	NULL
between	NULL
c-fos	NULL
and	NULL
Fra-2	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:5537	NULL
.	NULL

41	NULL
.	NULL

Yen	NULL
,	NULL
J.	NULL
,	NULL
R.	NULL
M.	NULL
Wisdom	NULL
,	NULL
I.	NULL
Tratner	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1991	NULL
.	NULL

An	NULL
alternative	NULL
splice	NULL
form	NULL
of	NULL
fosB	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
transcriptional	NULL
activation	NULL
and	NULL
transformation	NULL
by	NULL
fos	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:5077	NULL
.	NULL

42	NULL
.	NULL

Chen	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
E.	NULL
V.	NULL
Rothenberg	NULL
.	NULL

1994	NULL
.	NULL

Interleukin-2	NULL
transcription	NULL
factors	NULL
as	NULL
molecular	NULL
targets	NULL
of	NULL
cAMP	NULL
inhibition	NULL
:	NULL
delayed	NULL
inhibition	NULL
kinetics	NULL
and	NULL
combinatorial	NULL
transcription	NULL
roles	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:931	NULL
.	NULL

43	NULL
.	NULL

Havran	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1987	NULL
.	NULL

Characterization	NULL
of	NULL
murine	NULL
cytolytic-helper	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

Nature	NULL
325:65	NULL
.	NULL

44	NULL
.	NULL

Telander	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
E.	NULL
N.	NULL
Malvey	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Mueller	NULL
.	NULL

1998	NULL
.	NULL

Evidence	NULL
for	NULL
repression	NULL
of	NULL
IL-2	NULL
gene	NULL
activation	NULL
in	NULL
anergic	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:1460	NULL
.	NULL

45	NULL
.	NULL

Izquierdo	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
J.	NULL
Leevers	NULL
,	NULL
C.	NULL
J.	NULL
Marshall	NULL
,	NULL
and	NULL
D.	NULL
Cantrell	NULL
.	NULL

1993.	NULL
p21	NULL
``	NULL
couples	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
to	NULL
extracellular	NULL
signal-regulated	NULL
kinase-2	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:1199	NULL
.	NULL

46	NULL
.	NULL

Deng	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1994.	NULL
c-Fos	NULL
transcriptional	NULL
activity	NULL
stimulated	NULL
by	NULL
H-ras-activated	NULL
protein	NULL
kinase	NULL
distinct	NULL
from	NULL
JNK	NULL
and	NULL
ERK	NULL
.	NULL

Nature	NULL
371:171	NULL
.	NULL

47	NULL
.	NULL

Su	NULL
,	NULL
B.	NULL
,	NULL
E.	NULL
Jacinto	NULL
,	NULL
M.	NULL
Hibi	NULL
,	NULL
T.	NULL
Kallunki	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
Y.	NULL
Ben-Neriah	NULL
.	NULL

1994	NULL
.	NULL

JNK	NULL
is	NULL
involved	NULL
in	NULL
signal	NULL
integration	NULL
during	NULL
costimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
77:727	NULL
.	NULL

48	NULL
.	NULL

Marais	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
Wynne	NULL
,	NULL
and	NULL
R.	NULL
Treisman	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
SRF	NULL
accessory	NULL
protein	NULL
Elk-1	NULL
contains	NULL
a	NULL
growth-factor-regulated	NULL
transcriptional	NULL
activation	NULL
domain	NULL
.	NULL

Cell	NULL
73	NULL
;	NULL
381	NULL
.	NULL

49	NULL
.	NULL

Franklin	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
V.	NULL
Sanchez	NULL
,	NULL
F.	NULL
Wagner	NULL
,	NULL
J.	NULL
R.	NULL
Woodgett	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Kraft	NULL
.	NULL

1992	NULL
.	NULL

Phorbol	NULL
ester-induced	NULL
amino-terminal	NULL
phosphorylation	NULL
of	NULL
human	NULL
c-jun	NULL
but	NULL
not	NULL
JunB	NULL
regulates	NULL
transcriptional	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:7247	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

